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Abstract
The lives of more than six million people in the United States are negatively impacted by
the diagnosis of Advanced Heart Failure. Financial burden, repeated hospitalizations, and
declining quality of life account for poor outcomes. Implantation of a left ventricular assist
device (LVAD) has offered the promise of improved financial, clinical, and functional outcomes
for those awaiting or ineligible for heart transplantation. Right Heart Failure (RHF), however,
threatens positive outcomes as it remains the leading cause of mortality and morbidity following
LVAD placement. Despite extensive research, there is no comprehensive tool for RHF risk
assessment and stratification for this population. The D.N.P. project aimed to adapt and
implement a scoring tool for such assessment. Providers rated the assessment tool to be feasible
and useful in practice. Though limited by a small number of LVAD patients, RHF risk was found
to fluctuate for each patient throughout the phases of care, and no single parameter consistently
trended in the same direction as the combined score. This pilot project should inspire future
projects aimed at identifying risk for RHF which can offer opportunities for preventative care
and realization of all positive outcomes for LVAD recipients.
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Chapter 1
Introduction, Significance, and Problem Statement
Introduction
Right heart failure (RHF) is the most common postoperative complication following
implantation of a left ventricular assist device (LVAD) for advanced left heart failure. Advanced
heart failure negatively impacts the lives of over six million people in the United States today,
accounts for approximately one million hospitalizations, and is mentioned on over 300,000 death
certificates annually (Centers for Disease Control and Prevention [CDC], 2020). For this
population, resistance to medical treatment and repeated hospitalizations are associated with
worsening prognosis, poor quality of life, and a projected rise in healthcare cost from $39 billion
currently to $53 billion by 2030 (Gohar et al., 2018, p. 35). Though heart transplantation remains
the gold standard treatment for end-stage heart failure, the LVAD has become an accepted
alternative treatment for this disease. It offers an effective solution for a population of patients
otherwise facing an unmatched and unpredictable availability of compatible donor organs
(Harshvardhan & Satsangi, 2020).
The durable LVAD was introduced in 2001 and became a life-saving option for bridging
patients to heart transplantation. The one-year survival rate of candidates waiting with an LVAD
reportedly increased from 10.2% during 1996-2000 to 70% during 2011–2017 (Bakhtiyar et al.,
2020). Since then, the indication for use has been expanded to include destination therapy for a
growing number of LVAD recipients who are not candidates for transplantation. Once
implanted, the LVAD restores organ perfusion, preserves physical strength, and improves overall
survival rate by 27% (Bowen et al., 2020). Significantly improved survival and quality of life
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outcomes are consistently reported, independent of the indication for LVAD placement (Emani
et al., 2016).
Despite successes with advanced heart failure treatment, RHF remains the primary cause
of morbidity and mortality following LVAD implantation, reducing the 80% one-year survival
rate to 59% (Ali et al., 2020). Morbidities associated with the development of RHF include
prolonged hospital length of stay, coagulopathy, altered drug metabolism, cardiac cachexia,
diuretic resistance, gastrointestinal bleeding, and decreased quality of life (Lambert & Tueteberg,
2015).
The Problem Statement
Concomitant implantation of a durable RVAD would be the ideal solution to the problem
of RHF after LVAD. However, there is no such FDA-approved device currently available.
Treatments aimed at preventing or minimizing RHF have proven effective, though are dependent
on the accurate identification of risk for impending RHF associated with LVAD placement.
Numerous studies have aimed to identify the best preoperative predictors of right heart
failure after LVAD (Bellavia et al., 2017; Hayek et al., 2014 & Lampert & Tueteberg, 2015).
The majority have been conducted in single centers with retrospective data collection, using
small sample populations. Inclusion and exclusion criteria, the specific parameters evaluated, and
the definitions of RHF have differed between studies, therefore offering minimal opportunity for
comparison or conclusion. A recent meta-analysis reported conflicting evidence with several of
the proposed risk assessment instruments and parameters reaching statistical significance yet
having small effect sizes (Bellavia et al., 2017). Though the evidence offers minimal consensus
for accurate assessment of risk for RHF after LVAD, there is clear agreement that the need to do
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so is essential to producing the positive outcomes this technology offers patients with advanced
heart failure.
The lack of a comprehensive instrument for reliably predicting RHF has resulted in the
inaccurate and inconsistent assessment of risk and a failure to recognize worsening right
ventricular dysfunction before progression toward irreversible, debilitating RHF. This D.N.P.
project assessed the use of an adapted, evidence-based RHF risk assessment instrument for
LVAD candidates and recipients at a large medical center.
Significance of the Problem
Advanced heart failure is a progressive condition associated with several cardiovascular
disease processes. The prevalence of advanced heart failure continues to rise steadily with the
aging population and improved survival from acute cardiovascular disease. It is the most
common diagnosis in hospitalized patients over 65 years of age and the most frequently
associated with 30-day readmission (Nair et al., 2020).
Despite significant advances in medical therapies, the diagnosis of advanced heart failure
carries a 30-40% mortality rate, varying with severity (Nair, 2020). Though heart transplantation
significantly improves survival, less than 20% of eligible candidates will receive a compatible
donor heart (Bakhtiyar et al., 2020). Forty-five percent of patients on the waiting list may lose
eligibility or will not survive to transplantation (McLarty, 2015).
The life expectancy for patients with advanced heart failure is less than 12 months. Over
the past decade, the LVAD has increased one-year survival to 80%, and two-year survival to
70% for patients with advanced heart failure, either as a bridge to transplantation or as
destination therapy (Wagner et al., 2020). Placement of an LVAD has the potential to increase
life expectancy to over ten years (Gustaffson & Rogers, 2017). Despite these successes, as many
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as 50% of recipients may develop postoperative right heart failure, threatening loss of the
survival, clinical, and quality of life improvements this technology promises (Baxter et al.,
2019). These patients will have a sixfold increase in mortality (Farag et al., 2021). Nair (2020)
found a reduction in one-year survival to 71%, and two-year survival down to 54%. Along with
the loss of promised longevity, patients with RHF after LVAD will experience a higher
incidence of coagulopathy and hemorrhage, respiratory and renal failure, postoperative length of
stay, hospital readmissions, failure to bridge to transplantation, loss of independence, and an
overall poorer quality of life (Baxter et al., 2019 & Kurihara et al., 2017).
The severity of sequelae is associated with the severity of right heart failure following
LVAD implantation (Baxter et al., 2019). Failure to identify risk for impending RHF can result
in a missed opportunity for the timely employment of alternate treatments proven to protect and
support the struggling right heart. Therefore, the focus must remain on the urgent need to reliably
assess RHF risk if this devastating complication is to be prevented or its severity minimized
(Raina & Patarroyo-Aponte, 2018). Fulfillment of this need is critical to mitigating poor
financial, clinical, and functional outcomes for the rapidly growing population of LVAD
recipients.
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Chapter 2
Review of Literature, Project Models, Organizational Assessment, SWOT, and Aims
Review of the Literature
A search was performed to review evidence for the prediction of RHF following LVAD
implantation. Databases searched included Ovid Medline, Scopus, and Google Scholar. Search
terms included: RHF, LVAD, RHF after LVAD, prediction of RHF after LVAD, risk for RHF
after LVAD, right ventricular function and left heart failure, cardiac reserve function,
Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS), and
European Registry for Mechanically Assisted Circulatory Support (EUROMACS). The articles
were limited to English language, humans, and adults. Articles before 2011 were eliminated,
except for three review articles. All articles without the primary focus on right heart failure after
LVAD and those evaluating pulsatile flow LVADs were eliminated. 23 articles of the remaining
54 articles, were eliminated for poor study quality rendering each non-contributory. 27 articles
published in 2011 or later, and one classic review article from 2010 were evaluated for inclusion
and exclusion criteria, specific endpoints, and parameters and risk scores proposed for prediction
of RHF after LVAD (see Appendix A). A total of 29 articles published were included in this
review (Appendix B).
Implantation of an LVAD has become an accepted alternative to heart transplantation for
patients with end-stage left heart failure. It offers an effective solution for a population of
patients who otherwise face unmatched and unpredictable availability of compatible donor
organs (Harshvardhan & Satsangi, 2020). Most patients with severe left heart failure are
classified as American College of Cardiology Foundation/American Heart Association
(ACCF/AHA) Stage D Heart Failure (HF) and have New York Heart Association Class IV HF
5
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symptoms. Approximately 80% of patients will improve to class I-II symptoms six months after
LVAD implantation (Kiernan et al., 2016). Significantly improved survival and quality of life
outcomes are consistently reported (Emani et al., 2016).
Despite efficient left ventricular function, LVAD recipients may manifest symptoms of
worsening HF attributed solely to RHF (Kanwar et al., 2020). RHF is the primary complication
after LVAD placement for 3.9-53% of recipients (Ali et al., 2020). The critical need for reliably
predicting and preventing RHF has been the motivation for this extensive research.
Most research studies have been conducted in single centers using retrospective data
collected from small sample populations. Inclusion and exclusion criteria, the specific
parameters evaluated and definitions of RHF endpoints have lacked consistency and may
contribute to the broad range of documented incidence and mortality associated with RHF after
LVAD. Initial analysis of the evidence finds little consensus regarding parameters predictive of
RHF and offers minimal opportunity for comparison (Bellavia et al., 2017; Hayek et al., 2014).
A synthesis of the collective evidence, however, does support the following:
1). Right Ventricle (RV) dysfunction coexists with severe left heart failure.
2). Parameters that measure RV reserve function determine risk.
3). LVAD placement acutely reduces RV reserve function, driving the need
to identify early risk.
4). RHF is the endpoint of a continuum beginning with subclinical RV dysfunction.
5). Critical events alter risk for RHF by reducing, restoring, or maintaining RV reserve,
allowing movement in either direction along the continuum.
6
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RV dysfunction coexists with severe left heart failure
The right and left ventricles are dependent on each other for producing cardiac output
adequate for perfusing all organs. Functional interdependence is achieved through a shared
septum and pericardium. Approximately 30% of right ventricular output is reliant on this
relationship (Kanwar et al., 2020). Changes in diameter, geometry, or contractility in one
ventricle directly affect function of the other (Kukucka et al., 2011). A unique embryonic origin
lends the RV the ability to dilate to accommodate increased volume imposed by a failing left
ventricle (LV). However, the RV is far less tolerant of pulmonary hypertension (PH) imposed by
LV failure (Meineri et al., 2012).
Eighty percent of patients with LV failure develop secondary PH (Rao et al., 2020).
Secondary PH also persists for a time following LVAD placement (Houston et al., 2016).
Attempting to maintain LV filling in the face of PH, the RV uses alternative, less efficient
contractility which eventually leads to RV muscle hypertrophy and dilation. These structural
changes are indicative of myocyte loss and diminishing contractility. Prolonged exposure to PH
or acute spikes in PH exhaust compensatory mechanisms ultimately leading to RV
decompensation (Ali et al., 2020). Decompensation is marked by evidence of end-organ
hypoperfusion and dysfunction (see Figure 1).
In a meta-analysis, Bellavia et al. (2017) concluded that nearly all LVAD recipients had
some level of preoperative RV dysfunction on echocardiogram. Newer three-dimensional (3D)
echocardiograms capable of detecting even subclinical RV dysfunction have added support for
this point of agreement (Aymami et al., 2018). In a comparison of parameters obtained on twodimensional (2D) and three-dimensional (3D) echocardiograms, Magunia (2018) reports that the
American Society of Echocardiography recommends combining parameters from either
7
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technology with clinical signs to estimate preoperative RV dysfunction, allowing a more
accurate determination of risk for RHF following LVAD insertion. Wagner et al. (2020) studied
112 LVAD recipients retrospectively to find the majority with preoperative RV dysfunction.
Stratifying recipients on a spectrum of compensated to decompensated RV function showed a
relationship between the severity of RV dysfunction preoperatively and the development of early
postoperative RHF. Though there is substantial agreement regarding the existence and
significance of preoperative RV dysfunction in response to PH, there is little consensus
concerning parameters that best assess risk for RHF following LVAD placement (Grant et al.,
2021).
Figure 1
Sequelae of Left Heart Failure
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Parameters Measuring RV Reserve Function Determine Risk
RV reserve is the difference between maximal compensatory capacity and basal
function. It is the safety margin that allows RV resilience to maintain its output despite
progressive PH or additional insult (Grunig et al., 2020). Once compensatory mechanisms such
as altered contractility and RV dilation are exhausted, decompensated RV dysfunction is marked
by a comparably smaller, underfilled LV and subsequent end-organ hypoperfusion.
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Though RV dysfunction exists, it is the ability to maintain function or the remaining reserve
function that determines risk for the development of RHF after LVAD. RV dysfunction as a risk
factor becomes relative to reserve function, the more accurate measure of risk. The less RV
reserve function at any level of RV dysfunction, the greater the risk of decompensation and
progression to postoperative RHF. Inconclusive findings and lack of consensus has likely
resulted from failure to assess RHF risk with consideration for compensatory expenditure and
evidence of decompensation (see Figure 2).
Figure 2
Components of Right Ventricular Reserve Function

Parameters representing each of the components of RV reserve: PH, RV compensation,
and RV decompensation, studied independently have been inconsistent in their ability to
accurately predict RHF. Additionally, the use of individual parameters has been outperformed by
combinations of parameters representing two or more components (see Figure 3). Combined
parameters offer evidence of the strong inverse relationship between diminishing RV reserve and
increasing risk for RHF after LVAD insertion (Del Rio et al., 2019).
Pulmonary Hypertension. PH has been recognized as the greatest culprit of structural
and functional RV changes in the setting of LV failure (Rao et al., 2020). Parameters measuring
pulsatile resistance as opposed to those measuring static resistance were found to represent PH
9
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Figure 3
Parameters Constituting RV Functional Reserve
ABBREVIATION
Pulmonary Hypertension Parameters

NAME

FORMULA

INTERPRETATION

PVR

Pulmonary Vascular Resistance

Resistance to mean flow

TPG

Transpulmonary Gradient

Pulmonary arterial pressure -pulmonary capillary
wedge pressure/CO
Alveolar pressure – intrapleural pressure

DPG

Diastolic Pulmonary Gradient

PAS

Pulmonary Artery Systolic Pressure

PACi

Pulmonary Arterial Compliance Index

Ea

Pulmonary Elastance

PAPi

Pulmonary Artery Pulsatility Index

Pulmonary artery systolic – pulmonary diastolic
pressure/right atrial pressure

LAVi

Left Atrial Volume Index

Obtained by direct measurement
Obtained by direct measurement
Obtained by direct measurement
Derived from echocardiographic right atrial
diameter measurement/BSA
Derived from echocardiographic right atrial
diameter measurement
Derived from echocardiographic left atrial
diameter measurement/BSA

Right heart preload
Right heart preload
Left heart preload
Right ventricular size

RVEDAi

Right Atrial Pressure
Central Venous Pressure
Pulmonary Capillary Wedge Pressure
Right Ventricular End Diastolic Volume
index
Right Ventricular End Diastolic Area Index

Contractility Parameters
RV FAC

Right Ventricular Fractional Area of Change

Obtained by echocardiographic measurement

TAPSE

Tricuspid Annular Plane Systolic Excursion

Obtained by echocardiographic measurement

TrV

Tricuspid Regurgitation Velocity

Obtained by echocardiographic measurement

RVEF

Right Ventricular Ejection Fraction

RVLS

Right Ventricular Longitudinal Strain

Obtained by echocardiographic or hemodynamic
measurement
Obtained by echocardiographic measurement

RVSWI

Right Ventricular Stroke Work Index

0.0136 x right ventricular stroke volume x (mean
pulmonary artery pressure – right atrial pressure)

Estimate of the % of change within the
right ventricle between systole and diastole
Estimate of the displacement of the
tricuspid valve from end diastole to end
systole
Estimate of right ventricular systolic
pressure
Estimate of % end diastolic volume ejected
during RV systole
Measure of right ventricular free wall
deformation during peak systole
Estimation of RV workload and
contractility. Implies work capacitance

Decompensation Parameters
BUN

Blood Urea Nitrogen

Obtained from blood sample analysis

Cr

Creatinine

Obtained from blood sample analysis

GFR

Glomerular Filtration Rate

Obtained from blood sample analysis

T bili

Total Bilirubin

Obtained from blood sample analysis

ALT

Aspartate Transaminase

Obtained from blood sample analysis

AST

Alanine Transaminase

Obtained from blood sample analysis

MELD

Model for End Stage Liver Disease

Score based on renal replacement therapy,
creatinine, total bilirubin, INR and sodium

Dilation Parameters
RAP
CVP
PCWP
RVEDVi

Diastolic pulmonary artery pressure – pulmonary
capillary wedge pressure
Obtained by direct measurement
Right ventricular stroke volume – pulmonary
artery systolic – pulmonary diastolic
pressure/BSA
Pulmonary artery systolic pressure/right
ventricular stroke volume
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Net pressure applied to the lungs with
inspiration or positive pressure ventilation
Marker of pulmonary remodeling
Pressure in pulmonary artery during right
ventricular ejection
Index of pulmonary vascular elasticity

Reciprocal of compliance. Total right
ventricular overload including resistive and
pulsatile components.
Indirect measure of contractility at a given
right ventricular preload and afterload

Right ventricular size
Left heart afterload

Nitrogen waste remaining in
blood/Measure of kidney function
Creatinine waste from muscle breakdown
in blood/ Measure of kidney function
Rate of filtration of waste by kidney’s
glomerulus/Measure of kidney function
Bilirubin waste product of red blood cell
breakdown in blood/Measure of liver
function
Enzyme released from damaged liver
cells/Measure of liver function
Enzyme released from damaged liver
cells/Measure of liver function
Predictor of survival n setting of liver
disease
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more accurately. Neither, however, reached significance as individual predictors of RHF
(Bellavia et al., 2017; Grandin et al., 2015; Kimmalardjuk & Ruej, 2017; LoForte et al., 2018;
Loghmanpour et al., 2016; Marshall et al., 2020; Muslem et al., 2019 & Scott et al., 2020).
The best performing measures of pulsatile resistance were pulmonary arterial compliance
index (PACi), pulmonary elastance (Ea), and pulmonary arterial pulsatile index (PAPi). Though
similar, calculation of PAPi uniquely combines pulsatile resistance with a measure of RV
dilation. PAPi proved to be the most consistent independent predictor of RHF when compared to
all other calculations of PH (Kang et al., 2016 & Marshall et al., 2019). Grandin et al. (2015) and
Muslem et al. (2019) found that Ea and PACi performed comparably only when combined with a
measure of RV dilation. They also found LVAD recipients at the least risk for RHF when PH
and RV dilation were minimal. The greatest risk was associated with greater PH and greater RV
dilation. Those with greater PH and minimal RV dilation were found to have moderate risk for
postoperative RHF. Evaluation of PH relative to compensatory RV dilation did not reach
significance though did consistently improve discrimination for RHF. Relating PH to an RV
dilation supported the associations between increasing compensation, diminishing reserve
function, and increasing risk for RHF after LVAD.
Right Ventricular Compensatory Dilation. Parameters representing compensatory RV
dilation include qualitative descriptions of RV size and direct measurements of RV diameter
obtained by echocardiography as well as by hemodynamic pressure measurements. Central
venous pressure (CVP) and right atrial pressure (RAP) have been used interchangeably and are
cited in nearly every inquiry.
Compensatory dilation is a response to a backup of volume which occurs as
compensatory RV contractility becomes overwhelmed by increased or prolonged PH. Parameters
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of RV dilation have shown a relationship to declining RV reserve and increased risk for RHF
after LVAD. Elevations in RAP immediately preceding LVAD implantation, whether persistent
or increased from baseline, were associated with a three-fold risk of progression to RHF after
LVAD placement (Grandin et al., 2015).
Evidence suggests that RV dilatation approaching, or exceeding LV size is an indication
of diminishing reserve function with the loss of capacity to adequately fill the LV. Increased
preoperative ratios of RV:LV dilation outperformed isolated measures of RV dilation as an
independent predictor of RHF following LVAD (Kukucka et al., 2011). RV:LV dilation was the
only dilation parameter to significantly improve discrimination for RHF when combined with the
most cited risk scores, which at best, had performed modestly (Vivo e al., 2013).
Right Ventricular Compensatory Contractility. Traditionally RV contractility has
been equated with RV function, long believed to be the greatest determinant of RHF following
LVAD implantation. However, qualitative descriptions, semi-quantitative measurements, and
hemodynamic calculations representing RV contractility have repeatedly failed to show a
consistent association with postoperative RHF (Aymami et al., 2018; Bellavia et al., 2017; Grant
et al., 2012; Gumus et al., 2019; Imamura et al., 2015; Kiernan et al., 2015; Magunia et al., 2018;
& Scott et al., 2020). Similarly, surrogate parameters such as CVP have not been reliable
predictors of RHF and have instead led to delayed recognition of failing RV contractility,
diminishing RV reserve, and therefore risk for RHF after LVAD.
2D and 3D echocardiographs have allowed for quantitative estimations of right
ventricular ejection fraction (RVEF) and right ventricular longitudinal muscle strain (RVLS).
Both parameters are sensitive to early decreases in normal contractility, preceding evidence of
RV dilation. RVEF and RVLS were strongly associated with progression to RHF following
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LVAD when compared to traditional and surrogate parameters. Like all other parameters of RV
contractility, RVEF and RVLS demonstrated significantly augmented discrimination for RHF
when combined with parameters of PH, RV dilation, or both (Aymami et al., 2018; Kiernan et
al., 2015 & Scott et al., 2020). The combination of parameters representing PH with those of
early compensatory RV contractility and later compensatory RV dilation, have repeatedly shown
greater implications for diminishing RV reserve function and the threat of progression to RHF
than any single measure of RV contractility.
Right Ventricular Decompensation. Right ventricular decompensation is defined by
failure of compensatory mechanisms to maintain LV filling, sufficient for end-organ perfusion.
Measures of renal and liver function have been the most frequently reported and reliable
laboratory predictors of RHF after LVAD placement (Bellavia et al., 2017; Benjamin et al., 2020
& Hayek et al., 2014). These laboratory parameters may be maintained within normal ranges
when medical and mechanical support have been added to preserve, restore, or replace RV
and/or end-organ function. Quantification of support then also becomes an indicator for RV
decompensation and a predictor of postoperative RHF. Worsening organ function despite
escalating support indicates loss of reserve function and risk for rapid progression to RHF.
Assigned INTERMACS profiles depicting the progression from compensated RV
function to decompensated RV function have been included in several studies (see Figure 4).
Though not specific, lower profiles have been strongly associated with a worse prognosis for
RHF across all studies (Aymami et al., 2018). Significantly improved discrimination was
demonstrated when profiles were combined with parameters representing compensatory RV
contractility and dilation (Grant et al., 2012 & Loghmanpour et al., 2016).
The ALMA score uniquely combined parameters representing PH, RV compensation,
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Figure 4
INTERMACS Profiles
Profile 1

Critical cardiogenic
shock

Patients with life-threatening hypotension despite rapidly escalating inotropic support,
critical organ hypoperfusion, often confirmed by worsening acidosis and/or lactate
levels. “Crash and burn.”

Definitive intervention
needed within hours.

Profile 2

Progressive decline

Patient with declining function despite intravenous inotropic support, may be manifest by
worsening renal function, nutritional depletion, inability to restore volume balance
“Sliding on inotropes.” Also describes declining status in patients unable to tolerate
inotropic therapy.

Definitive intervention
needed within few
days.

Profile 3

Stable but inotrope
dependent

Patient with stable blood pressure, organ function, nutrition, and symptoms on continuous
intravenous inotropic support (or a temporary circulatory support device or both), but
demonstrating repeated failure to wean from support due to recurrent symptomatic
hypotension or renal dysfunction “Dependent stability.”

Definitive intervention
elective over a
period of weeks to few
months.

Profile 4

Resting symptoms

Patient can be stabilized close to normal volume status but experiences daily symptoms
of congestion at rest or during ADL. Doses of diuretics generally fluctuate at very high
levels. More intensive management and surveillance strategies should be considered,
which may in some cases reveal poor compliance that would compromise outcomes
with any therapy. Some patients may shuttle between 4 and 5.

Elective over weeks to
months as long as
treatment of episodes
restores stable baseline,
including nutrition

Profile 5

Exertion intolerant

Comfortable at rest and with ADL but unable to engage in any other activity, living
predominantly within the house. Patients are comfortable at rest without congestive
symptoms, but may have underlying refractory elevated volume status, often with renal
dysfunction. If underlying nutritional status and organ function are marginal, patient
may be more at risk than INTERMACS 4,and require definitive intervention.

Variable urgency, depends
upon
maintenance of nutrition,
organ function,
and activity.

Profile 6

Exertion limited

Patient without evidence of fluid overload is comfortable at rest, and with activities of
daily living and minor activities outside the home but fatigues after the first few
minutes of any meaningful activity. Attribution to cardiac limitation requires careful
measurement of peak oxygen consumption, in some cases with hemodynamic
monitoring to confirm severity of cardiac impairment. “Walking wounded.”

Variable, depends upon
maintenance of
nutrition, organ function,
and activity
level.

Profile 7

Advanced NYHA III

A placeholder for more precise specification in future, this level includes patients who are
without current or recent episodes of unstable fluid balance, living comfortably with
meaningful activity limited to mild physical exertion.
Transplantation or circulatory support may
not currently be indicated.
Modifiers for Profiles Possible Profiles to Modify
TCS-Temporary Circulatory Support can modify only patients in hospital (other devices
would be INTERMACS devices) Includes IABP, ECMO, Tandem Heart, Levitronix, BVS
5000 or AB5000, Impella.
1,2,3 in hospital.
A-Arrhythmia –can modify any profile. Recurrent ventricular tachyarrhythmias that have
recently contributed substantially to clinical compromise. This includes frequent ICD
shock or requirement for external defibrillator, usually more than twice weekly.
Any profile.
FF-Frequent Flyer – can modify only outpatients, designating a patient requiring frequent
emergency visits or hospitalizations for diuretics, ultrafiltration, or temporary intravenous
vasoactive therapy.
3 if at home, 4,5,6. A frequent flyer would
rarely be profile 7.

Variable urgency, depends
upon
maintenance of nutrition,
organ function,
and activity.

Adapted from “Right Atrial Pressure Predicts Mortality Among LVAD Recipients: Analysis of
the INTERMACS Database”, by Guglin, M., & Omar, H.R., Heart and Lung Circulation, p. 595,
10(4), with permission from Elsevier
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The ALMA score uniquely combined parameters representing PH, RV compensation,
and RV decompensation to stratify patients by the need for insertion of a temporary RVAD at the
time of LVAD implantation. The score implies a relationship between minimal RV reserve and
the highest risk for early postoperative RHF (see Figure 5). The score demonstrated 82.90%
sensitivity and 87.80% specificity for RHF after LVAD. ROC curve comparison to several other
parameters previously determined to be independent predictors showed a high ACU0.77(95% CI
0.06-0.88) (LoForte et al., 2018). Though promising, this tool has not been validated. The
EUROMACS RHF risk score which also incorporates components of RV reserve has been the
only score to demonstrate external validity (see Figure 6), (Silverton et al., 2020).
Though rarely studied, combining parameters of RV compensation with parameters of
decompensation appears to afford the greatest insight into the expenditure of RV reserve and
associated severity of risk for progression RHF.
LVAD placement acutely reduces right ventricular reserve function, driving the need to
identify early risk
Acute physiologic changes inherent in LVAD implantation highlight the significance of
tracking reserve throughout the perioperative period. LV unloading, the desired effect, correlates
with acute leftward shift of the intraventricular septum. This shift is devastating to a dilated RV
which has become heavily dependent on septal contraction (Gudejko et al., 2019). The RV is
further challenged by an abrupt increase in venous return as the LVAD increases left-sided
output (Gudejko et al 2019).
Parameters of PH were measured individually and in combination with parameters of RV
dilation and RV contractility at predetermined intervals following LVAD placement. The
relationship between PH, RV dilation, and RV contractility worsened in the immediate
15
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Figure 5
The ALMA Risk Score
Parameter
Destination Therapy

Score = 1
Yes

PAPi

< 2.0

RV/LV end diastolic diameter ratio

> 0.75

RVSWi

> 300 mm/Hg/ml/m 2 = 1

MELD score

> 17 = 1

Total score
4-5 indicates highest risk for requiring right ventricular assist device (RVAD) at time of LVAD
3

indicates high risk for requiring RVAD at time of LVAD unless temporary RVAD/pharmacologic support sufficient.

2

is a gray area in which isolated LVAD placement will be tolerated with appropriate pharmacologic/ temporary RVAD

0-1 Isolated LVAD placement will likely be tolerated

Developed from Loforte et al., 2018.

postoperative period and declined in a steep parallel manner during later postoperative intervals.
LV unloading should acutely relieve PH however, evidence suggests a more gradual reversal of
pulmonary hypertension. Persistent PH further challenges RV reserve in the early postoperative
phase (Houston et al., 2017). Gudejko et al. (2019) identified the combination of elevated
parameters of PH and persistently elevated measures of RV dilation most discriminatory for
severe postoperative RHF. Comparably, postoperative RHF requiring emergent temporary
RVAD placement was associated with a combination of elevated PH and worse RV contractility
(Imamura et al., 2016). All inquiries reported failure of independent PH, RV contractility, and
RV dilation parameters to correlate with postoperative RHF.
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Figure 6
The EUROMACS Right Heart Failure
Parameter
•
•
•
•
•

Points awarded

Severe RV dysfunction on echocardiogram
RAP: PCWP > 0.54
INTERMACS profile 1-3
Need for > 3 inotropic medications
Hgb < 10 g/dl

2.0
2.0
2.0
2.5
1.0

Score Interpretation
0-2

Low risk

2.5-4 Intermediate risk
>4

High risk

Developed from Soliman et al., 2018

RHF is the endpoint on a continuum beginning with undetectable Right Ventricular
Dysfunction
Proposed predictors and variations of INTERMACS RHF criteria have been unique to each
study (see Figure 7). Despite differences, the premise of all research has been a dichotomous
relationship between preoperative RV function and the development of RHF following LVAD.
This premise is brought into question by studies extending data collection into the intraoperative
and early postoperative phases. Findings from these studies support the more dynamic nature of
risk for RHF after LVAD (Gudejko et al., 2019; Kumar et al., 2020; LoForte et al., 2018;
Loghmanpour et al., 2016).
A score of maximal dependence on inotropic and vasoconstrictor medications during the
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Figure 7
INTERMACS Criteria for Right Heart Failure after LVAD Placement
▪
▪
▪
▪
▪
▪
▪
▪

Physical signs and symptoms of right heart congestion
Central venous pressure or right atrial pressure > 18 mm Hg
Pulmonary capillary wedge pressure < 18 mm Hg
Cardiac index > 2 L/minute
No tamponade or alternate diagnosis explaining clinical condition
Required inhaled pulmonary vasodilator
Required unplanned right ventricular device
Required inotropes > 7-14 days

Developed from Aymami et al., 2018

initial postoperative 48-hours combined with elevated measures of RV dilation was strongly
associated with RHF, independent of preoperative parameters (Kumar et al., 2020). Similarly,
increased RV dilation immediately before LVAD insertion was associated with postoperative
RHF regardless of earlier preoperative measures (Grandin et al., 2015). Intraoperative factors
associated with increased PH, reduced RV contractility, or increased dilation also independently
increased risk for postoperative RHF (Houston et al., 2017). A continuum of disease progression
from compensated RV function to RHF is supported by studies that collectively demonstrated
variable risk for development of RHF throughout the perioperative period, independent of
isolated preoperative risk factors.
Critical events alter risk by reducing, restoring, or preserving RV reserve, allowing movement
along a continuum
Several critical events, including LVAD insertion, accelerate the movement from
subclinical preoperative RV dysfunction with adequate reserve function, toward clinically
significant RHF. Progression toward RHF occurs as incremental increases in compensatory
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changes with corresponding decreases in RV reserve, render the RV less and less capable of
maintaining adequate output in the face of added insult. Large intraoperative volume or blood
product resuscitation showed a strong association with RHF post LVAD. Limitless RV dilation
observed upon opening the pericardium, and acute worsening of RV contractility immediately
following pericardium closure were also strongly associated with progression to postoperative
RHF, independent of all prior parameters (Gudejka et al., 2019). Like events resulting in
increased dilation or reduced contractility, any event causing a sudden spike in PH such as
acidosis and hypoxemia severely challenges RV reserve function and acutely increases risk for
postoperative RHF, regardless of timing (Houston et al., 2013).
Identification of critical events that may potentiate risk of progression to RHF offer the
opportunity to prevent their occurrence or minimize their impact. Interventions that preserve or
restore RV reserve mitigate risk for progression to irreversible RHF; A progression that parallels
a continuum from reversible end-organ ischemia to multisystem organ failure and inevitable
death.
Summary
Points of agreement derived from seemingly noncomparable study findings collectively
suggest abandoning the notion of predicting RHF using parameters defined by distinct points in
time. Rather the evidence advises the development of a comprehensive model for evaluating the
dynamic interaction between components of RV reserve throughout the perioperative period.
Preoperative pulmonary hypertension, RV dilation, compensatory RV contractility, and evidence
of decompensation agreeably place candidates at increased risk for progression to RHF.
However, the evidence also suggests flexibility in the parameters used to measure these
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components of RV reserve as it is the relationship amongst them that is most significant in the
determination of risk for RHF after LVAD insertion.
Project Management Model
Graham et al. (2006) identified knowledge creation and action as the two
interactive and essential components of the Knowledge to Action framework (KTA) which
steered the successful implementation of the D.N.P. project (see Figure 8).
Knowledge creation is depicted as a funnel through which information is gathered during
Inquiry, filtered during Synthesis, and then refined to meet the needs of intended users during
Tool Development (Graham et al., 2006). For the D.N.P. project, a comprehensive RHF risk
assessment instrument for LVAD patients was adapted from the ALMA risk assessment score.
Synthesis of evidence guided the extraction of relevance and relatedness amongst the myriad of
predictive parameters and definitions of RHF, unique to nearly every study. It also guided the
timing and frequency of assessment.
Phases of action encircling the knowledge funnel often begin with Problem
Identification. Gaps between clinical practice and evidence were realized during this project by
repeated movement between this phase and re-entry into the knowledge funnel. The preliminary
adapted instrument was tailored to the clinical setting and stakeholders during the Adaptation of
Knowledge. Assessment of Barriers and Facilitators was used to create an implementation plan
maximizing strengths and mitigating risks inherent within the system. Rotation of the
knowledge funnel was required upon entry into the Implementation of Tailored Interventions to
assist with selection of evidence-based, yet accessible risk parameters at the institution of
implementation. Monitoring Use of Tailored Knowledge proved integral as this project was
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dependent on consistent use of the risk assessment instrument. Continuous Evaluation of
Outcomes and fluid movement between all phases was intended to produce Sustained Use of
Knowledge for improved clinical and quality of life outcomes for both LVAD patients and care
providers (Graham et al., 2006).
Figure 8
Project Management Model: Knowledge to Action

From “Lost in the Knowledge Translation: Time for a Map”, by Graham,I ., Logan,T ., Harrison
n, M., Strauss, S., Tetro, J., Caswell,W . & Robinson, N., Journal of Continuing Education in the
Health professions,20 06,P. 19, 26, with permission from Wolters Kluwer Health, Inc.
Theoretical Model
The MAC Risk Assessment Decision Support Model was adapted from the work of
Synderman and Yoediono (2006) to guide RHF risk assessment instrument adaptation, methods
of implementation, and evaluation (see Figure 9). The model was originally intended to track
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individual risk for developing disease over time. The model was easily adapted for tracking
progression from preclinical RV dysfunction associated with LV failure, to irreversible RHF.
Directly comparable to progression toward RHF, according to this model, critical events
accelerate disease progression. The original model was used to identify biomarkers to detect
progression from baseline to irreversible disease. This same concept was applied to identifying
parameters that reliably predict progression toward RHF. Synderman and Yoediono (2006), also
included risk and monetary cost, both of which increased as the disease progressed. Placing the
continuum from subclinical RV dysfunction to RHF on the same graph allowed identification of
parameter values associated with increasing risk for progression. For the D.N.P. project,
monetary cost was replaced with expenditure of RV reserve to determine parameter values that
marked the progression from compensated, preclinical disease to decompensated, less reversible
disease.
Prospectively tracking risk and disease development affords the opportunity to provide
preventative and therapeutic interventions which mitigate risk for progression (Ginsburg, 2009).
The effect of these interventions can also be tracked as positive critical events. The adapted
model was applied to better understand the continuum of disease progression and expenditure of
functional RV reserve as they relate to positive and negative critical events, ultimately enabling
an appropriately dynamic assessment of risk for RHF throughout the perioperative course for
LVAD patients.
Organizational Assessment
System Description
The institution of implementation is a healthcare delivery system incorporating seven
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hospitals, a behavioral health network, a clinical care organization, a regional home care
Figure 9
Theoretical Model: MAC Risk Assessment Decision Support Model

Adapted from “Prospective Care: a personalized, preventative approach to
medicine”, by Synderman,R., & Yoediono Z. , 2006, Parmacogenomics, p. 7, 7(1),
with permission from Future Medicine Ltd.

system, senior care service, and a large rehabilitation and physical therapy network with over
350 locations throughout Connecticut and Rhode Island. The system employs a model of
Institutes, each sharing the mission of improving the health and healing of targeted populations
within the community they serve. Value is placed on offering advanced technology, innovation,
and a multidisciplinary approach to care delivery. Strategic planning and large investment led to
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the establishment of a Heart and Vascular Institute, intended to improve the timeliness of
preventative and restorative care for a community with highly prevalent heart disease and
associated mortality.
Setting.
The Heart Failure Center within the Heart and Vascular Institute employs and connects
an alliance of caregivers to meet the complex needs of patients with heart failure from the time
of diagnosis through death. The physician team is comprised of physicians with a specialty
certification in heart failure, medical cardiologists, cardiology interventionalist, and cardiac
surgeons. Advanced practice registered nurses (APRN), registered nurses (RN) and coordinators
are central to the integration of care for each subpopulation of patients receiving various
advanced treatments including mechanical circulatory support. Forums of communication that
foster a comprehensive, multidisciplinary approach to care are well established. Mechanical
circulatory support is offered on the main hospital’s campus. LVAD candidates and recipients
have a dedicated APRN team leader and Analytics Administrator. The multidisciplinary team
involved in the care of patients undergoing LVAD implantation also includes
echocardiographers, cardiac anesthesiologists, critical care intensivists, advanced critical care
providers, nurse managers, social workers, rehabilitation therapists, and RNs, most of who are
represented at weekly team meetings. This integrated setting supported the adaptation,
implementation, and evaluation of a comprehensive risk assessment for LVAD patients.
Need for the Project.
Patients referred to the center for LVAD implementation commonly have severe LV
failure despite maximal medical therapy. LVAD implantation as either a bridge to
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transplantation or as destination therapy has the potential to dramatically improve survival,
functional capacity, and quality of life. Development of RHF following LVAD will minimize or
eliminate these benefits often leading to a poorer quality of life, increased hospital readmissions,
failure to thrive, multisystem organ failure, and often death. Common to most programs, though
the opportunity for prevention of this complication exists, there was no standard RHF risk
assessment performed before, during, or following LVAD placement at the hospital of
implementation. A comprehensive RHF risk assessment for patients undergoing LVAD
placement was intended to contribute to the mitigation of potentially poor outcomes and the
realization of the many benefits of LVAD therapy.
Organizational Strengths, Weaknesses, Opportunities, and Threats (SWOT).
The primary strength of the healthcare system of implementation was its commitment to
providing all necessary resources for advanced mechanical circulatory support to patients with
advanced heart failure. State-of-the-art technology, maintenance of staff competency, and
established multidisciplinary networks provided the integration needed to implement changes in
practice.
Investment in state-of-the-art technology and maintenance of caregivers’ competence in
using technology allowed ready access to most recent and well-supported measures of RV
reserve for RHF risk assessment. Implementation of a comprehensive RHF risk assessment tool
for patients undergoing LVAD placement was supported by the nationally recognized team of
caregivers and by replication of previously successful processes used for implementation of
similar assessment tools within the system. Additionally, a resolute analytics administrator,
participation in a national registry, and well-developed local databases enabled project
evaluation.
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System weaknesses centered around the lack of a standard RHF risk assessment for care
planning. Though minimal, a lack of motivation to use the tool may have been attributed to an
underestimation of RHF prevalence before implementation with nonspecific data collection,
missing data, and limited RHF outcomes reported by the national registry. Communication and
implementation were challenged by the large number of providers across the perioperative
phases of care needing to improve documentation of risk parameters and to calculate RHF risk
scores during the COVID pandemic. These challenges compounded the anticipated weakness in
the system related to varying levels of knowledge and skills amongst these providers.
External threats to successful implementation and evaluation of the tool included rapidly
changing technology which may render data incomparable. This also means higher costs of
equipment as well as costs incurred by extensive and continuous staff education. The lack of
externally validated RHF assessment parameters or scores may also challenge the adoption of the
proposed risk assessment instrument. Overall, organizational strengths appear capable of
overcoming these barriers. (see Appendix C).
Aims
1). Adapt a model for assessing risk for RHF associated with LVAD implantation.
2). Implement and evaluate the RHF risk assessment model for LVAD candidates.
3). Make recommendations for sustainability and scalability of the model’s use for added groups
of patients.
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Chapter 3
Methods, Project Timeline, Human Subjects Consideration, Leadership and Stakeholder
Engagement, and Business and Financial Considerations
Overview of Methods
Right heart failure RHF is the primary cause of morbidity and mortality after placement
of a durable LVAD. Lack of a comprehensive tool to reliably assess RHF has resulted in failure
to recognize risk and progression to irreversible and debilitating heart failure for a substantial
number of LVAD recipients. The goal of this D.N.P. project was to adapt, implement and
evaluate an evidence-based RHF assessment instrument for patients undergoing LVAD
implantation.
The D.N.P. project was a quality improvement project conducted at a large medical
center. Providers caring for LVAD patients in and across the preoperative intensive care unit
(ICU), operating room, and postoperative ICU, received education and encouragement to use the
adapted RHF risk assessment instrument for patient presentations and care planning. Evaluation
of the project included a prospective analysis of providers’ ratings of the assessment instrument.
A retrospective descriptive analysis of parameters and scores was also used to glean information
regarding RHF associated with LVAD implantation.
Aim 1: Adapt a model for assessing risk for RHF associated with LVAD implantation.
Adaptation/Development Plan
The evidence addressing risk factors for RHF after LVAD implementation was reviewed
resulting in the one model for assessing RHF risk, the ALMA RHF Risk Score, supported by
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several other studies identifying comparable parameters for risk of developing RHF after LVAD
implantation.
The LVAD RHF risk assessment instrument was adapted from the ALMA Right Heart
Failure Risk Score developed by LoForte et al., 2018, intended to predict early postoperative
RHF as an indication for implantation of a temporary right ventricular assist device (see Figure
6). The adapted model (see Figure 10) for this project included parameters that are supported by
the evidence as comparable and are currently obtained for all LVAD candidates and recipients
within the hospital diagnostic testing suites, cardiovascular ICUs, and operating room. Internal
and external heart failure experts were invited to rate parameters under consideration for the tool.
(see Appendix E).
Figure 10
LVAD Right Heart Failure Risk Assessment Instrument
LVAD Right Heart Failure Risk Score Calculation:
0-1 Point

Add 1 Point for Each Category if at Least One Parameter Applies
Category 1: Pulmonary Resistance:
o
PAPI (PAS-PAD/CVP ) < 2.0
Category 2: Right Ventricular Dilation:
o
CVP >16
o
CVP/PCWP > 0.5
Category 3: Right Ventricular Function:
o
REF < 25
o
RVSWI >300
o
> Mild RV dysfunction on echo
o
TAPSE < 1.6
Category 4: Renal /Liver Function
o
Creatinine >2
o
New CVVH, HD
o
MELD Score >17
Category 5: Support
o
> 1 Inotropic or vasopressor medication
o
Mechanical ventilator dependence
o
IABP
o
RVAD
o
ECMO
Total Points
RHF Risk Score Interpretation:

4-5 Highest risk

2-3 Intermediate risk
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Expert reviewers were sent instructions for reviewing the adapted tool (see Appendix F).
They also received a reference table of parameter definitions and measurements (see Figure 11).
Experts were asked to rate parameters within the domains defined by RV reserve components.
The parameters were rated for relevance to RHF and for their accuracy in measuring each
parameter under consideration for inclusion in the adapted risk assessment instrument.
Figure 11
Definition and Measurement of Parameters for Expert Review
ABBREVIATION
NAME
Pulmonary Hypertension Parameters

FORMULA

INTERPRETATION

PACi

Pulmonary Arterial
Compliance Index

Index of pulmonary vascular elasticity

Ea

Pulmonary Elastance

PAPi

Pulmonary Artery
Pulsatility Index

Right ventricular stroke volume –
pulmonary artery systolic –
pulmonary diastolic pressure/BSA
Pulmonary artery systolic
pressure/right ventricular stroke
volume
Pulmonary artery systolic –
pulmonary diastolic
pressure/right atrial pressure

Obtained by direct measurement
Obtained by direct measurement
Obtained by direct measurement

Right heart preload
Right heart preload
Left heart preload

Derived from echocardiographic
or hemodynamic pressure
measurement/BSA
Derived from echocardiographic
or hemodynamic pressure
measurement/BSA
Derived from echocardiographic
diameter at end diastole
measurements/BSA
Derived from echocardiographic
diameter at end diastole
measurements/BSA

Right ventricular diameter

Obtained by echocardiographic
or hemodynamic measurement

Estimate of % end diastolic volume ejected during RV systole

Compensation Parameters
RV Dilation Parameters
RAP
CVP
PCWP
RVEDVi

Right Atrial Pressure
Central Venous Pressure
Pulmonary Capillary
Wedge Pressure
Right Ventricular End
Diastolic Volume index

LVEDVI

Left Ventricular End
Diastolic Volume index

RVEDAI

Right Ventricular End
Diastolic Area Index

LVAEDI

Left Ventricular End
Diastolic Area Index

Contractility Parameters
RVEF

Right Ventricular Ejection
Fraction

Reciprocal of compliance. Total right ventricular overload including resistive and pulsatile
components.
Indirect measure of contractility at a given right ventricular preload and afterload

Left ventricular diameter

Right ventricular diameter

Left ventricular diameter

A slide presentation was developed for educating providers who were asked to document
parameters in the electronic record, calculate, and use the score in practice (see Appendix J). A
one- page fact sheet was also developed, distributed by email and posted in ICUs. The fact sheet
content included information regarding the purpose of the RHF risk score, an explanation of
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parameters included in the score, instructions for calculation, and recommendations for its use
(see Appendix K). A laminated pocket reference card for score calculation was developed,
distributed to providers, and made available in ICUs. (see Appendix L).
An RHF risk score entry option was added to the critical care provider hand-off for
LVAD candidates and recipients. This hand-off existed in the electronic record however was not
part of the permanent record. It is an optional worksheet under the ownership of providers and
can be edited by any provider who has access to it (see Appendix M).
Evaluation Plan.
The expert responses for relevance and accuracy of parameters required the use of a
rating scale from one to four, ranging from not relevant or accurate to highly relevant or accurate
(see Appendix G &H). Calculation of an Item Content of Validity Index (I-CVI) was performed
for each item to derive the proportion of experts who judged the item relevant and/or accurate
(Polit et al., 2007). An I-CVI of > 0.79 for a parameter was initially determined to be favorable
for retaining the parameter for the final instrument. This was later lowered to a threshold of >
0.67 based on the number of expert respondents (see Appendix I).
Aim 2: Implement and evaluate the RHF risk assessment model for LVAD candidates.
Implementation Plan
The adapted RHF risk assessment instrument was introduced during a pre-established,
weekly multidisciplinary team meeting in which 15 to 20 LVAD candidates and recipients
are discussed. The project leader, who is the critical care representative, delivered a
PowerPoint presentation to the team’s preoperative, intraoperative, and postoperative
provider representatives. (see Appendix J). Providers were asked to reorganize routinely
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collected parameters to calculate and incorporate into discussion, RHF risk scores during
weekly meetings from September through December 2021.
The one-page fact sheet and laminated pocket reference RHF scoring cards were
distributed by email and made available in the ICUs. The team representatives were also
asked to encourage implementation of the instrument in their respective departments.
Initially, provider education was to be delivered by representatives in each phase of care.
Representatives were to voluntarily assume the following responsibilities; however, the
process was altered given the limitations imposed by the COVID 19 pandemic.
1. Share a Zoom recording of the PowerPoint presentation or arrange for a live
presentation by the project leader.
2. Distribute the one-page fact sheet and pocket reference to providers involved in the
care of LVAD patients.
3. Post the one-page fact sheet and reference card in the charting and sign-off
locations within their respective departments. The use of a simple fact sheet and
scoring reference, particularly posted in these locations, had been a common and
effective method for disseminating similar information to providers.
4. Facilitate documentation of tool parameters on the provider handoff.
5. Facilitate calculation and incorporation of the adapted RHF risk score into
presentations and care planning for LVAD patients.
6. Collect and provide prospective feedback during weekly email communication with
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the project leader.
With unforeseen limitations, the project leader assumed these responsibilities.
The Analytics Administrator of the Center for Advanced Heart Failure continued to
collect parameters during the baseline, preoperative, intraoperative, and postoperative phases of
care for LVAD patients, as this was the routine practice. The Analytics Administrator agreed to
create a password-protected file of coded, deidentified demographic, and parameter data. The
project leader was granted access to this separate, coded, and encrypted file.
Evaluation Plan
A combination of formative and summative evaluation was employed to determine
usefulness of the RHF risk assessment tool in practice. A post-implementation survey consisting
of six items and requiring ratings using a five-point Likert scale ranging from strongly agree to
strongly disagree was distributed to providers. Items addressed the providers’ perception of the
instrument’s feasibility, usefulness, and impact on clinical decision-making (see Appendix O ).
Providers were sent an email including a link to the REDCap application used by the hospital.
They were invited to read an information sheet and consent to participate (see Appendix N).
Those who clicked a “yes” were sent to the survey in the REDCap application where coded
responses were stored for analysis. The scores from all respondents were evaluated for normality
of distribution and were presented as mean scores (see Table 1).
The project leader organized the de-identified data collected into the adapted RHF risk
assessment tool to arrive at RHF risk scores. RHF risk scores were calculated using parameters at
baseline, immediately preoperatively, intraoperatively and within one week postoperatively(see
Tables 4,5,6,&7). Based on previous activity, it was anticipated that six patients would be
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implanted with an LVAD during the project duration however, a total of four patients were
implanted during that period. A descriptive analysis of demographic data, parameters, and scores
was performed to inform RHF following LVAD implantation. Incidence of RHF in LVAD
recipients during the three-month implementation phase could not be compared to incidence of
RHF in LVAD recipients during the six months prior to implementation as the diagnostic criteria
had been revised, delaying INTERMACS outcomes reports. Also, outcomes beyond the
postoperative data collection point were not included in this project.
Aim 3: Make recommendations for sustainability and scalability of the instrument’s use
for added groups of patients.
Sustainability
The D.N.P. project will be presented to the leadership of the Heart Failure Center and the
Heart and Vascular Institute. Recommendations will be made regarding further implementation
of the risk assessment instrument over an extended time for additional LVAD candidates and
recipients. A request will be made to INTERMACS for reporting RHF outcomes with analysis of
the parameters included in the risk assessment score. INTERMACS encourages such requests
and has standardized RHF diagnostic criteria for registries and future trials which will facilitate
comparison between studies.
Scalability
Recommendations will be made for collaborating with information technology to
construct an algorithm for electronic record population of RHF risk assessment parameters and
automatic risk score calculation. This scoring will be embedded into provider documentation by
use of a smart phrase, mirroring a similar algorithm for risk of readmission currently in use.
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Providers can then be alerted when patients’ risk for RHF increases during any phase of care.
This would allow providers the opportunity to employ preventative interventions and would also
satisfy the need for dynamic risk assessment which is supported by the evidence.
Following repeated and extended use for assessment of LVAD patients; risk for
postoperative RHF, adaptation, and use of the assessment instrument for other patient
populations with similar risk for RHF, will also be proposed to the administration of the Heart
and Vascular Institute.
Dissemination Plan
The D.N.P. project will be submitted for presentation at the National Teaching Institute &
Critical Care Exposition and the Annual Right Heart Symposium, 2023-2024. It will be
presented in the institution of implementation as well. The project will also be submitted to one
of the following for publication to Circulation: Heart Failure Journal, Journal of Heart and Lung
Transplantation, Heart and Lung Journal, Nurse Practitioner, and the Critical Care Nurse Journal.
Project Timeline
A draft of the adapted tool for review was completed in July 2021. Expert panel review
was conducted during August 2021. The adapted instrument was finalized by September 1, 2021.
The PowerPoint presentation was used to introduce the project and background information
during a pre-established multidisciplinary meeting on September 8, 2021. Representatives from
the departments involved in the care of LVAD candidates and recipients and the project leader
shared information with providers from September 9 through October 9, 2021. Implementation
of the tool by providers began during September 2021 and continued through December 17,
2021. Providers received email and in-person communications weekly, during the
implementation period. They also received a final email containing a link to the post-
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implementation survey on December 17, 2021 and were asked to complete the survey by January
17, 2022 (see Appendix D).
Human Subjects Consideration.
This D.N.P. Project was determined a quality improvement project by the Institutional
Review Board at Yale. The Nursing Research Council and the Institutional Review Board at the
institution of implementation also reviewed and approved this D.N.P. project, as was required for
all projects with anticipated future publication.
Leadership and Stakeholder Engagement
As the project leader of this quality improvement project, the D.N.P. candidate adapted
the RHF risk assessment instrument, with the support of an expert panel, the APRN Project
Manager, and the physician Project Sponsor. The project leader developed and presented an
educational program for all providers. The leader also conducted all data analysis and reported
findings to all provider stakeholders at the conclusion of the project. The patients were the
primary stakeholders whose outcomes may have been positively impacted by the implementation
of the RHF risk assessment. The Heart Failure multidisciplinary team and the providers
interacting with patients and their families were also primary stakeholders. These stakeholders
were supportive of the project. Their knowledge base may have been increased and knowledge
variability among providers reduced. The ICU providers were instrumental in facilitating
implementation of the instrument in practice and provided a post-implementation rating of the
risk score. The Project Manager facilitated communication with, and amongst members of the
multidisciplinary team. The Analytics Administrator made possible the analysis of patient data
and provided the project leader with necessary education regarding INTERMACS. Other key
stakeholders were the members of the expert panel who found value in the project and expressed
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interest in future multicenter participation. A stakeholder analysis has been included (see Figure
12).
Figure 12
Stakeholder Analysis
Name

Title/Role

Project Engagement

Estimated Priority

Special interest in right heart Failure

High

1

Weekly updates on project planning & Progress

Project Manager, LVAD APRN

Self - motivated, initiates several quality improvements

High

1

Weekly updates and participation in project planning

Coordinator

projects central to all patients, families & caregivers

Operational Leader, APRN

Postoperative RHF

High

1

Care recipients

Varied/Individual, consented to LVAD work up

High

1

Medical Director Mechanical

Leadership, well-connected nationally

High

1

Monthly updates on project development & progress

Leadership

High

2

Monthly updates on project development & progress

Supportive

Intermediate

2

Monthly updates on project development & progress

Supportive

Intermediate

2

Monthly updates on project development & progress

Skilled

Intermediate

2

Include in planning and tool development/parameter

Perform preoperative cardiac

Skilled/expertise in hemodynamic parameter

Intermediate

1

catheterization

interpretation

Perform LVAD
insertion &
participate in
preoperative and
postoperative
management
Perform
Intraoperative
echocardiogram &
medical
management
Provide immediate
preoperative &
postoperative
management

Skilled in invasive
procedures/interventions

Intermediate

1

Include in planning and tool
development/parameter
selection, multidisciplinary
meetings and INTERMACS
report analysis

Skilled in echocardiogram and
perfusion management

Intermediate

1

Expert in hemodynamic monitoring
& critical care

High

1

Include in planning and tool
development/parameter
selection, multidisciplinary
meetings and INTERMACS
report analysis
Include in planning and tool
development/parameter
selection, multidisciplinary
meetings, daily care rounds.

Data Manager

Data collection &
INTERMACS
submission

Supportive, Expert in data retrieval
& INTERMACS reporting

High

1

Cardiology Residents &
Fellows

Provide immediate
preoperative &
postoperative
management
Provide
preoperative and
late postoperative
management,
source of referral
for Heart failure
care

Supportive

High

1

Intermediate

2

Heart Failure Physician Project

Project Sponsor, Heart Failure

Sponsor

Certified Cardiologist

Heart failure APRN Project Manager

APRN Project Leader

Characteristics/ Interest

Potential Management Strategies

& progression

CTICU, DNP candidate
LVAD Candidates & Recipients,
Families/significant others
Heart Failure Physician

Keep informed of risk for RHF & related workup/tailored interventions

Circulatory Support
Heart failure Physician

Chief of Cardiology & Director
of Heart Failure Center

Heart Failure Physician

Heart Failure Certified
Cardiologist

Heart failure Physician

Heart Failure Certified
Cardiologist

Echocardiographers

Perform preoperative &
postoperative echocardiograms

Cardiac Interventionalist

selection
Include in planning and tool development/parameter
selection, multidisciplinary meetings and
INTERMACS report analysis

Cardiothoracic
Surgeons

Cardiothoracic
Anesthesiologist

Cardiology &
Cardiothoracic ICU
intensivist, attendings,
Advanced practice
providers & RNs

Outpatient Care
Providers

Supportive, established relationship
with patients, expert in diagnosis of
worsening heart failure assessment
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individual patient
course/outcomes

Risk For RHF After LVAD/MA Cyr

Business and Financial Considerations
The cost of standard care for the six LVAD admissions anticipated for this project
would have been $1,695,000 or $282,500 per admission. The project adds an estimated $5600 to
each admission. After initial one-time costs, the cost of continued use of the RHF risk
assessment tool would be reduced to $2500 per admission (see Figure 13). The benefits of its use
would include avoidance of the direct, indirect, and intangible costs associated with RHF after
LVAD as well as increased access to LVAD implantation.
Figure 13
Project Budget
Program Expense

Estimated Cost

Staffing
(Expert panel, providers)
Services
(Scientist assistance/ design & data analysist)
Equipment & Supplies
(paper, copies, lamination)
Total Expense

$24,789.00

Actual
Cost
$18,956.00

$ 2,970.86

$ 2,970.86

$ 100.00

$

$27,859.86

$22,400.14

473.28

Actual costs included that of the four LVAD admissions

Up to 50%, or two of the four patients included in this project, will likely develop RHF
following LVAD implantation. Increased ICU and hospital length of stay, additional diagnostic
procedures, and treatments would contribute to increased direct and indirect medical costs of
over $166,000 per implant admission, far surpassing the $5600 spent to prevent or mitigate the
impact of RHF. Cost avoidance for 50% of the average 15 admissions per year, beyond the
project, would increase to over $1,222,500 annually with the prevention of RHF.
Direct and indirect medical costs related to RHF after discharge primarily include
increasingly frequent readmissions within 30 days of discharge and throughout the remaining
months of life. Each RHF readmission after LVAD costs approximately $19,000 compared to
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$12,000 for similar admissions prior to LVAD placement (Shreibati et al., 2017). These more
costly readmissions could be completely avoided with the use of the risk assessment tool and
prevention of RHF.
Prevention of RHF would also result in additional avoidance of approximately $12,000$15,000 each year related to increased outpatient visits, diagnostic testing, increased need for
medications, treatments, rehabilitative, home, and long-term care (Urbich et al., 2020). Like
readmissions, these avoidable costs escalate as RHF inevitably progresses.
Societal and personal costs account for the remainder of indirect and intangible costs which
could be avoided with prevention of RHF after LVAD. Loss of income impacts LVAD
recipients, their families, informal caregivers, and employers. Such losses directly associated
with advanced heart failure contributed to over $12.4 billion of lost income in the U.S. during the
year 2020 (Urbich et al., 2021). Though actual dollars can be attached to medical care and to loss
of income, there is no dollar amount capable of placing value on the loss of promised
productivity, independence, and longevity. These losses result in worsening pain, suffering,
depression, and overall quality of life for LVAD recipients with RHF.
Use of the risk assessment instrument and prevention of RHF after LVAD would
improve the financial, clinical, and quality of life outcomes for LVAD recipients. Improved
outcomes would then drive improved access to LVAD implantation. Recently, Medicare and
Medicaid coverage expanded to include all indications for LVAD because of evidence
demonstrating comparable outcomes for bridge to transplant and destination therapy (Urbati et
al., 2021). Prior to the 2020 revision, there was limited access to LVAD as a destination therapy
based on presumed worse outcomes. Though indication for LVAD no longer inhibits access,
poor outcomes associated with the development of RHF continue to limit it.
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RHF after LVAD raises mortality rate six-fold with remaining months of life consisting
of multiple hospital readmissions, need for additional, costly care as well as a quality of life often
worse than that prior to implantation. In a healthcare reimbursement system moving toward
value-based care, the prevalence of RHF and its associated poorer outcomes will invariably
contribute to declining reimbursement and limited access to LVAD implantation for many living
with advanced heart failure.
The cost-benefit of this project was achieved by enhancing knowledge of providers and
equipping them with an instrument for reliably assessing risk for RHF after LVAD.
Identification of risk affords providers the opportunity to prevent RHF or minimize its severity.
Any dollar amount attached to this benefit would be an underestimation of its positive impact on
the healthcare system, society, and most importantly, those living with advanced heart failure.

39

Risk For RHF After LVAD/MA Cyr

Chapter 4
Results
Results
Parameter Selection
The need for a comprehensive assessment of risk for RHF following LVAD implantation
served as the motivation for the quality improvement project. The project aimed to address this
care gap by adapting and implementing a RHF risk assessment instrument. Adaptation of the
instrument began with identification of 22 evidence-based parameters measuring the factors
contributing to right heart reserve.
Parameters under consideration for inclusion in the adapted RHF risk score assessment
instrument and content validity evaluation forms were emailed to ten experts. Initial written
communication was sent during July 2021. A second communication was sent during August
2021. The response rate was 30%. Three of the ten invited experts provided an evaluation of all
parameters’ relevance to risk of RHF after LVAD. Parameters of pulmonary hypertension, right
ventricular dilation, right ventricular function, and end-organ perfusion were additionally
evaluated for accuracy of measurement. The I-CVI for each parameter was calculated based on
responses from the three content experts (see Table 1). Proportion relevance and accuracy ratings
were consistent among the three experts.
Pulmonary Hypertension. This section included three items. For relevance and
accuracy, the I-CVI ranged from 0.00-1.00. The PAPi I-CVI was 1.00 for both relevance
(M=3.67) and accuracy (M=3.67). None of the experts rated PACi or Ea as relevant or accurate.
Item PAPi was retained in the final version of the RHF risk assessment instrument. Items PACi
or Ea were not retained based on content validity findings.
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Right Ventricular Dilation. This section included five items. For relevancy as well as
accuracy, the I-CVI ranged from 0.00-1.00. The CVP I-CVI was 1.00 for both relevance
(M=4.00) and accuracy (M=4.00). The CVP:PCWP I-CVI for relevancy was 0.67 (M=3.00).
The CVP:PCWP I-CVI for accuracy was 1.00 (M=4.00). RV:LV diameter I-CVI was 1.00 for
both relevance (M=3.33) and accuracy (M=3.33). None of the experts rated RVEDVI:LVEDVI
or RVEDAI:LVEDAI as relevant or accurate. Items CVP and CVP:PCWP were retained in the
final version of the RHF risk assessment instrument. Item RV:LV diameter was not retained in
the final version of the instrument as it was not a measure reported for LVAD recipients at the
institution of project implementation. Items RVEDVI:LVEDVI and RVEDAI:LVEDAI were
not retained in the final version of the RHF risk assessment instrument based on content validity.
Right Ventricular Function.This section included three items. The I-CVI for both
relevance and accuracy ranged from 0.00-1.00. RVLS I-CVI was 0.33 for relevance (M=2.00)
and 0.00 for accuracy. This item was not retained in the final instrument based on content
validity. The RVEF I-CVI was 0.33 for both relevance (M=2.00) and accuracy (M=2.00).
Though this item did not meet inclusion criteria, it was retained based on evidence, consistent
measurement at the institution of project implementation, and consensus among the project
leader, project manager, and project sponsor. RVSWI I-CVI was 1.00 for both relevance
(M=4.00) and accuracy (M=4.00). This item was retained in the final version of the RHF risk
assessment instrument.
End Organ Perfusion. This section included three items. The I-CVI range was
consistently 0.67 for relevance and ranged from 0.67-1.00 for accuracy. Item MELD I-CVI was
0.67 for both relevance (M=3.00) and accuracy (M=3.33). Creatinine I-CVI was 0.67 for
relevance (M=3.00) and 1.00 for accuracy (M=4.00). Lactate I-CVI was 0.67 for relevancy
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(M=2.67) and 1.00 for accuracy (M=4.00). Items MELD and creatinine were retained in the final
version of the RHF risk assessment instrument. Though lactate did meet inclusion criteria, it was
not retained as it is not a measure routinely reported for LVAD recipients at the institution of
project implementation.
Medical Support. This section included two items rated for relevance to right ventricular
decompensation. The I-CVI ranged from 0.33-0.67. Inotropic requirement I-CVI was 0.33
(M=2.33). Vasopressor requirement I-CVI was 0.67 (M=2.67). Both items were retained in the
final version of the RHF risk assessment instrument. Though inotropic support did not meet
inclusion criteria, it was retained based on evidence and consensus among the project leader,
mentor, and sponsor.
Mechanical Support. This section included six items rated for relevance to right
ventricular decompensation. The I-CVI ranged from 0.00-0.67. None of the experts rated IABP
requirement as relevant. Temporary RVAD I-CVI was 0.67 (M=2.67). Temporary LVAD I-CVI
was 0.33 (M=2.00). Mechanical ventilation I-CVI was 0.67 (M=2.67). Renal replacement I-CVI
was 0.33 (M=2.00). ECMO requirement I-CVI was 0.33 (M=1.67). Mechanical ventilation and
temporary RVAD were retained for the final RHF risk assessment instrument. Temporary LVAD
was not retained in the final instrument based on content validity findings. Though IABP, renal
replacement, and ECMO requirements did not meet inclusion criteria, these items were retained
in the final instrument based on evidence.
Of those parameters scored, most parameters retained for the final instrument had an ICVI > 0.67 for both relevance and accuracy. The I-CVI expectation was lowered from > 0.79 as
a score of 0.67 was achieved when at least two of the three respondents scored the parameter
favorably. Though meeting I-CVI criteria, lactate and RV:LV diameter were excluded as neither
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was routinely obtained at the institution of implementation. RVEF, a measure of right ventricular
function did not meet I-CVI criteria yet was retained. This parameter was well supported by
evidence and the two experts rating the parameter unfavorably provided comments indicating an
unfamiliarity with the parameter (Aymami et al., 2018; Kiernan et al., 2015 & Scott et al., 2020).
Parameters of medical and mechanical support were rated for relevance to RHF. Though
these parameters generally scored lower than all other parameters, they were retained. Evidence
suggests that right heart reserve and correspondingly, risk for RHF, are underestimated when
these parameters are excluded. Despite achieving low RHF risk scores, patients requiring support
are considered at greater risk than those who achieve the same scores without support (Kumar et
al., 2020).
Even with an I-CVI <0.67, requirements of inotropic support, renal replacement, and
IABP, were also retained for the final instrument. Expert comments indicated these parameters
were scored down because of their low specificity for risk of RHF. Inotropic support is a primary
criterion and renal replacement, is a secondary criterion for the diagnosis of postoperative RHF
according to the most recent consensus statement of the Mechanical Circulatory Support
Academic Research Consortium (ARC) (Kormos et al., 2020). IABP was also included as it
serves to increase coronary artery perfusion. Research presented at the 2021 annual Right Heart
Symposium identified right ventricular ischemia as a culprit of myocardial cell pathophysiology
associated with right heart compensation and decompensation (DiCarli, 2021).
The final instrument included fifteen parameters (see Figure 10). In addition to the
thirteen retained parameters based on expert panel and evidence evaluation, subjective right
ventricular echocardiographic function and TAPSE were also included based on discussion with
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the project manager and project sponsor as well as on the consistent availability of these
parameters observed during preliminary field observation and project planning.
Table 1
Expert Panel Parameter Rating
__________________________________________________________________________________
Relevance Mean I-CVI Accuracy Mean I-CVI Comments Retain
Expert A B C
A B C
Parameter
Pulmonary
Hypertension
PAPi
3 4 4 3.67 1.00 3 4 4 3.67 1.00
Y
PACi
1 2 2 1.67 0.00 1 1 2 1.33 0.00
N
Ea
1 2 2 1.67 0.00 1 1 2 1.33 0.00
N
RV Dilation
CVPCVP:PCWP
4 4 4 4.00 1.00 4 4 4 4.00 1.00
Y
CVP:PCWP
3 2 4 3.00 0.67 3 3 4 3.33 1.00
Y
RV:LV Diameter
3 3 4 3.33 1.00 3 3 4 3.33 1.00
N
RVEDVI:LVEDVI 1 2 2 1.67 0.00 1 2 2 1.67 0.00 Not Used
N
RVEDAI:LVEDVAI 1 2 2 1.67 0.00 1 2 2 1.67 0.00 Not Used
N
RV Function
RVLS
1 3 2 2.00 0.33 1 2 2 1.67 0.00 Not Used
N
RVEF/REF
1 1 4 2.00 0.33 1 1 4 2.00 0.33 Not Used
Y
RVSWI
4 4 4 4.00 1.00 4 4 4 4.00 1.00
Y
End Organ Function
MELD
2 4 3 3.00 0.67 2 4 4 3.33 0.67
Y
Creatinine
4 1 4 3.00 0.67 4 4 4 4.00 1.00
Y
Lactate
3 1 4 2.67 0.67 4 4 4 4.00 1.00
N
Medical Support
Inotropic Infusion
4 1 4 2.33 0.33
All on it
Y
Vasopressor Infusion 3 1 4 2.67 0.67
All on it
Y
Mechanical Support
IABP
2 1 2 1.67 0.00
Y
Temporary RVAD
4 0 4 1.67 0.67
Y
Temporary LVAD
3 1 2 2.00 0.33
N
Mechanical Ventilation3 3 2 2.67 0.33
Y
Renal Replacement 3 1 2 2.00 0.33
Y
ECMO
3 2 0 1.67 0.33
Y
___________________________________________________________________________
Y=Yes, N=No, I-CVI= Item Content Validity Index
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Implementation
Implementation began with a presentation of the project during a weekly LVAD
multidisciplinary team meeting. A follow-up email containing project information and the RHF
risk assessment instrument reference card was attached to distributed meeting minutes. Though
provider use was not specifically evaluated, calculation of the score was requested with the intent
of obtaining providers’ evaluation of the feasibility and usefulness of the RHF risk score. There
was no evidence of score calculation or discussion during meetings following the presentation.
This may have been partially attributed to the departure of the project manager who had been a
liaison between the project leader and the multidisciplinary group, conversion to zoom meeting
forums, and time constraints placed on presenting providers amidst the COVID pandemic.
The initial project design proposed the identification of representatives who would share
information with providers in the preoperative, intraoperative, and postoperative phases of care
respectively. Given the many providers spanning 24 hours of care, seven days a week, and the
increased workload experienced during the pandemic, the implementation plan was revised. The
project leader presented repeated-in-person education sessions and weekly follow-up visits to
providers working in the preoperative and postoperative intensive care units. As a result, these
providers received consistent information regarding the background, risk assessment scoring
process, and application to clinical practice. The project leader posted the one-page reference
sheet and placed laminated reference cards in the units as planned. Providers in these units did
document calculated risk scores on provider hand-outs in both units for each of the four LAVD
patients included in the pilot project.
The intraoperative anesthesiology leadership was provided with the same verbal and
written information to share with providers. A follow-up email containing the provider

45

Risk For RHF After LVAD/MA Cyr

information sheet, risk assessment instrument, and an offer to provide in-person education, was
sent. There was no reply and no evidence of intraoperative calculation of the risk score. Verbal
follow-up revealed the preferred use of the intraoperative echocardiogram to assess right heart
function yet interest in what the project informed at its completion.
Provider Evaluation
All providers working in the preoperative and postoperative ICUs received an invitation
to complete a 6-item survey for evaluation of the RHF risk assessment instrument, following
implementation. Twelve providers responded. Using a Likert scale, providers consistently agreed
the instrument was simple to use (M=4.50), valuable (M=4.10), and useful in practice (M=4.50).
All providers agreed with continued (M=4.10), routine use, (M=4.10) of the instrument for
LVAD recipients. Three of the twelve providers responded “do not agree or disagree” with the
instrument’s impact on clinical decision-making (M=3.80) (see Table 1).
Table 2
Provider Survey Responses

Responses: 1=Strongly Disagree, 2=Disagree, 3=Do not Agree or Disagree,
4=Agree, 5=Strongly Agree

Disease Characteristics
A total of four patients underwent LVAD implantation during the implementation period.
All patients were diagnosed with either idiopathic or ischemic cardiomyopathy at least two years
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prior to admission. Prehospital NYHA classes ranged from III- IV. INERMAC profile at the
time of admission ranged from 1-3. All patients were implanted with a heartmate 3 device for
destination therapy.
Prehospital Parameters of Right Heart Reserve and Right Heart Failure Risk Scores
Pulmonary hypertension was evaluated for 75% of patients with a mean PAPi of 4.33,
when PAS (M=33.00), PAD (M=16.20), and CVP (M=7.50) values were recorded. Right
ventricular dilation was evaluated for all patients by a mean CVP of 7.50. Documentation of a
PCWP (M=12.00) for 75% of patients allowed the calculation of a CVP:PCWP (M=0.37).
Echocardiographic right ventricular function was evaluated by documented normal
function for 50% of patients, mildly reduced function for one, and moderately reduced function
for the fourth patient. One patient had a recorded TASPE of 1.40. No information was available
for evaluation of end-organ perfusion however, none of the patients were receiving renal
replacement therapy. Seventy-five percent of patients were receiving medical support before
admission with a continuous home milrinone infusion. One patient was not on medical support
before hospital admission. None of the patients were receiving mechanical support before
admission. No patient had complete data available for right heart risk score calculation.
Considering missing data, two patients had a minimal risk score >2.00 (intermediate risk), one
had a minimal risk score >1.00 (lowest risk), and a fourth had a risk score >0.00 (lowest risk).
Preoperative Parameters of Right Heart Reserve and Right Heart Failure Risk Scores
Pulmonary hypertension was evaluated for 75% of patients by a mean PAPi of 2.11,
when PAS (M=35.67), PAD (M=18.70), and CVP (M=5.00) values were recorded. Right
ventricular dilation was evaluated for 75% of patients by a mean CVP of 5.00. Documentation
of a PCWP (M=23.10) for 75% of patients allowed the calculation of a CVP:PCWP (M=0.30).
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Right ventricular function was evaluated for 75% of patients by a recorded mean REF of 14.67.
End organ perfusion for 100% of patients was evaluated by a mean creatinine of 1.45 and a mean
MELD score of 9.40 using recorded creatinine, (M=1.45), total bilirubin (M=0.70), Sodium
(M=132.80), and INR (M=1.30) values. None of the patients were receiving renal replacement
therapy preoperatively. Seventy-five percent of patients were receiving medical support. Two
patients received continuous milrinone infusions, while one received both milrinone and
dobutamine infusions. One patient was not on medical support preoperatively. Seventy-five
percent of patients required preoperative mechanical support. Two patients underwent IABP
insertion with one of those patients undergoing IABP removal before LVAD implantation. A
third patient required both IABP and mechanical ventilation. Incomplete data on one patient did
not allow a right heart risk score calculation. The remaining three patients had a mean risk score
of 4.00 (highest risk) with one patient scoring a 3.00 (intermediate risk), one scoring a 4.00
(highest risk), and a fourth scoring a 5.00 (highest risk).
Intraoperative Parameters of Right Heart Reserve and Right Heart Failure Risk Scores
There were no recorded parameters allowing intraoperative evaluation of pulmonary
hypertension, right heart dilation, or end-organ perfusion. Available data was also insufficient
for calculation of right heart failure risk scores. Echocardiographic right ventricular function
was evaluated by documented normal function for one patient, mildly reduced for a second
patient, and moderately reduced for the remaining two patients. All recipients required
intraoperative medical support with a continuous milrinone infusion. One patient additionally
required dobutamine and epinephrine infusions. All patients required mechanical support with
routine intraoperative mechanical ventilation. Two patients had an IABP in place with one
undergoing removal intraoperatively.
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Postoperative Parameters of Right Heart Reserve and Right Heart Failure Risk Score
Postoperative evaluation was performed between two and six days (M= 4.00) following
LVAD implantation. Pulmonary hypertension was evaluated for 75% of patients by a mean PAPi
of 1.42 using recorded PAS (M=33.00), PAD (M=20.00), and CVP (M=9.25) values. Right
ventricular dilation was evaluated by a mean CVP of 9.25. There were no recorded PCWP
values for CVP:PCWP calculation. Right ventricular function was evaluated for 100% of
patients by a mean RVEF of 19.50. End organ perfusion was evaluated for 100% of patients by
a mean creatinine of 1.33 and for 75% of patients, by a mean MELD score of 15.10 using
documented creatinine (M=1.33), total bilirubin (M=0.20), sodium (M=133.80), and INR
(M=3.30) values. One patient was missing a documented total bilirubin value. None of the
patients were receiving renal replacement therapy. Seventy-five percent of patients were
receiving medical support. Two patients received continuous milrinone infusions while another
received a continuous dobutamine infusion. No patient required postoperative mechanical
support. Patients had a mean postoperative right heart risk score of 2.75 (intermediate risk). Two
patients scored a 4.00 (highest risk), one scored a 3.00 (intermediate risk) and the fourth patient
scored a 1.00 (lowest risk).
The small sample size and missing data points did not allow statistical analysis or
generalization of findings. A descriptive analysis of each patient’s data did render further insight
into the phenomenon of right heart failure after LVAD implantation (see Appendix P). It was this
analysis that offered significant implications for improvement and expansion of the project.
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Chapter 5
Discussion and Conclusions
Discussion
Expert Panel
Unfamiliarity with a number of RHF risk parameters amongst the small number of
responding experts led to lack of support for parameters otherwise, well supported in the
literature. In a repeat cycle of the quality improvement project, evaluation of parameters by a
larger and more diverse expert panel should be elicited. This may be achieved by increasing the
number of invitations distributed as well as by providing frequent follow-up communication
during an extended response time.
Implementation
Implementation was altered for the ICU providers included in the quality improvement
project. This revision was associated with successfully eliciting these providers’ use of the RHF
risk assessment instrument in practice. A second cycle of the pilot project should include
repeated, in-person education sessions for intraoperative and multidisciplinary team providers as
this may have contributed to the ICU providers’ participation. Though both the multidisciplinary
group members and intraoperative providers were verbally supportive, email fatigue and
increased workload during the pandemic may have contributed to the comparably lower
participation rate. One-on-one and frequent communication with physicians and
anesthesiologists, outside of the multidisciplinary meetings may also foster participation in the
next cycle of the quality improvement project. The same education process should again be
repeated for ICU providers. The addition of voluntary representatives from both day and night
shifts for each of the care units would reinforce providers’ level of knowledge, their collection of
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appropriate parameters, and their use of the RHF risk score. Finally, emphasis on the alignment
of information garnered from the pilot project with the new INTERMACS guideline for
improved data collection and a refined definition of postoperative RHF may motivate increased
participation in future project cycles.
Provider Evaluation of Instrument
The preoperative, intraoperative, and postoperative ICU providers were asked to calculate
RHF risk scores while caring for LVAD patients, with the intent of evaluating the instrument at
the end of the implementation period. They consistently agreed that the instrument was useful,
simple to use, and should be routinely incorporated into LVAD patients’ assessments. The
instrument’s clinical impact was more frequently rated with a “Do not agree nor disagree”
response when compared to other survey questions. Because provider use was not the focus of
the project, lack of consistent use and documentation of the score by all providers likely
contributed to this response. Future projects focusing on providers’ use of the score and
designating a location for documentation common to all providers would allow for a more
accurate evaluation of the score’s impact on clinical care and outcomes for providers and
patients. Ultimately, an algorithm should be built into the electronic record to allow consistent
calculation of risk scores, automatic documentation at set intervals, and communication amongst
all providers.
Risk of RHF Following LAVD Implantation
A descriptive analysis of patent data did trend toward supporting conclusions derived from
the evidence. All patients diagnosed with left ventricular failure for > 2 years had evidence of
right heart dysfunction with variable degrees of compensation and decompensation before
LVAD placement. Most parameters failed to consistently trend with risk for right heart failure
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scores. Reliance on any one of these parameters could have led to an overestimation or
underestimation of risk. More consistently, an RVEF/REF > 25 did contribute to increased RHF
risk scores however, data for this parameter was limited.
Consistent with the literature, pulmonary hypertension worsened throughout the
perioperative course for all patients. This worsening, however, was most often independent of
increasing, decreasing, or persistent risk for RHF across the phases of care.
The one parameter most widely used for determining risk for right heart failure, CVP,
was the least likely to contribute to right heart failure risk scores. Though the CVP trends were
inconsistent with those of RHF risk scores, the criteria for a CVP of 16 should be modified for
future projects. A CVP of 16 is now the ARC criteria for diagnosing RHF. To recognize risk
toward this endpoint, the tool should be revised to award a point for a CVP > 10.
Most patients were admitted on a single inotropic medication. The risk assessment tool
did not account for the requirement of additional support which would indicate increased risk for
progression to RHF. Accordingly, the RHF risk score should be revised to award points for
requirement of additional therapies to produce a more accurate assessment of risk.
Though missing data limited analysis, the variability of parameters, requirement for support,
and RHF risk scores throughout the phases of care were consistent with a continuum of right
ventricular dysfunction progressing toward RHF. Critical events either restored, preserved, or
reduced right heart reserve thereby increasing or decreasing risk scores. Patient C’s data best
illustrates this continuum with worsening risk scores after a critical decline in heart function at
admission followed by an improving risk score once critical supportive therapy was added (see
Appendix P).
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Future cycles of this project should be revised to allow retrospective chart review of a
larger population of LVAD patients that minimizes missing data points and include RHF
outcomes. Statistical analysis would more clearly define the relationship between parameters,
scores, and outcomes while also further validating the RHF risk assessment instrument.
Scalability and Sustainability
The D.N.P. project provides a foundation for future projects which aim to validate the
RHF risk assessment instrument and the concept of right heart reserve. Instrument validation will
begin with repeated review by an expanded and more diverse expert panel. The findings of the
pilot project and instrument revisions will be communicated to all stakeholders in the system.
Through use of the Knowledge to Practice Model, the implementation process will be improved
for continued integration and evaluation at the current organization. The long-term goals involve
the integration of a comprehensive RHF risk assessment into care of all patient populations at
risk for RHF and future multicenter participation.
Sustained integration of the RHF risk assessment into practice will be facilitated by the
development of an algorithm for automatic calculation. The algorithm will facilitate common
documentation of RHF risk in a designated electronic record location by all providers, across all
phases of care. This will contribute to continuous evaluation and data for progressive
improvement in patient outcomes.
The concept of right heart reserve will also be further developed as a theoretical model
and validated through the activities described. The framework will be validated as a foundation
for clinical assessment, treatment, and physical activity prescriptions associated with RHF as
well as for the failure of other organ systems and disease progression. Information regarding the
RHF risk assessment instrument, the concept of right heart reserve, and the role of the D.N.P.
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will be disseminated in journal, textbook, and newsletter publications, as well as in conference
presentations.
Conclusion
The need for assessing risk for RHF after LVAD has been strongly agreed upon since the
implantation of the first durable LVAD in 2001. This quality improvement project piloted the
use of an adapted RHF risk assessment instrument and the newly defined concept of right heart
reserve, based on over thirty years of clinical observation and a thorough synthesis of seemingly
unrelated research findings. Though limited by a small number of LVAD patients and providers,
the findings suggest that the instrument is feasible, useful, and may inform risk for right heart
failure more closely than any single parameter.
Accurate identification of risk is an essential first step in preventing RHF for the
realization of the clinical, quality of life, and financial benefits of successful LVAD
implantation. Clinical outcomes, driven by the new guidelines for diagnosing and reporting RHF
after LVAD, are predicted to reveal an incidence of post-LVAD RHF beyond that previously
recognized. The next generation of LVADs will likely be wireless, eliminating clinical and social
barriers to implantation yet adding to its expense. Potentially improved access to care will
become increasingly dependent on positive patient outcomes which drive reimbursement.
Presentation of this quality improvement project both in journal and conference communications
should inspire future projects aimed at answering the intensifying need to predict and prevent
RHF following LVAD implantation.
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Appendix A
Prisma Flow Chart: Right Heart Failure Following Right Heart Failure

SCREENING

IDENTIFICATION

Records identified through
Google Scholar database
(n=146)

Records identified through
Scopus database
(n=638)

Records identified through
OVID database
(n=331)

(n=1116)

Duplicate elimination
(n-362)

(n=754)

Earlier than 2011 elimination
(n-67+3 outliers)

(n=695)

Unrelated title elimination
(n-324)

(n=366)

Unrelated abstract elimination
(n-91)

(n=275)

Unrelated Full article
elimination
(n-153)
Pulsatile flow LVAD
elimination
(n-17)
Poor quality or non-contributory
(n-53)

ELIGIBILITY

(n=122)

(n-105)

INCLUDED

(n=52)

Rescreening for RHF prediction

focus
(n-23)
(n=29)

Figure 1 Flow diagram to show number of studies remaining at each stage of literature review.
Source: From Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group. (2009).
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.
PLOS Medicine, 6(7), e1000097. https://www.doi.org/10.1371/journal.pmed.1000097.
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Appendix B
Literature Matrix: Right Heart Failure Following LVAD Implantation
Does use of a RHF risk assessment instrument provide information regarding the development of RHF after LVAD implantation?

Title,
Author,
Date

Purpose

Sample

Design

Primary
Enndpoint

Secodary
Endpoint

Additional
Endpoints

Results

Limitations

Implications for
Practice

Level of
Evidence

Determine if
quantitative
measures of
RV size & function
improve
risk
stratification for
RHF after LVAD
beyond validated
scores.

•158 of 191
consecutive
patients
•>18 years old
•Mean age
56+ 13 years
•79% male
•49%
•Total bilirubin
level within 2
weeks of echo
•Complete echo &
hemodynamic
heart evaluation by
echo &cardiac
catheterization
INTERMACS profile
1-2
•Isolated CF-LVAD
under
cardiopulmonary
bypass on a
beating heart
•94 Heartmate II
•57 Heartware
HVAD
•7 Jarvis 2000
•4 tricuspid
repair
•5 undefined
concomitant
valve surgery
•Stanford

•Retrospective
consecutive
cohort
•Prospective
registry of
patients
referred for
LVAD
•Observational

•RHF<30day
-RAP >16
-Inotropes >7 days

•RHF<30days
•Unplanned
RVAD for
-Progressive RVF
on echo,
-RAP > 16
-Increased
inotrope
-End organ
dysfunction

•Readmission for
heart failure
->24 hours in
hospitals
-lactate, serum
creatinine, LFTs
•Heart transplant
•Death

•RHF (38%)
•Unplanned RVAD
(12%)
within 24 hours
•Heart
transplant (9%)
•No difference
among devices
•Early morbidity &
mortality > with
RHF
•>Early mortality if
RHF & no RVAD
•Heart
transplant (9%)
•Existing scores
predictive of RHF
performed
moderately
-CRITT & EUROMAC
best
•Strong association
with RHF:
-RV function (RVLS)
-RV size (RVEDAI &
RVESAI),
-RAPRAP/PCWP
-total bilirubin and
INTERMACS profile
strongly associated
with RHF
•3-fold RHD if RVLS
& RVEDAI elevated

•Limited
generalizability:
-Modified
INTERMACS
definition
with inhaled
prophylactic
NO routine
preventing >RHF

•Limited
generalizability:
-Modified
INTERMACS
definition
with inhaled
prophylactic
NO routine
preventing >RHF

JBI level 3c

STUDY 1
The Incremental
Value of Right
Ventricular Size
and Strain in the
Risk Assessment of
Right Heart Failure
Post - Left
Ventricular Assist
Device
Implantation
Aymami, M.
Amsallem, M.
Adams, J.
Sallam, K.
Moneghetti, K.
Wheeler, M.
Hiesinger, W.
Teuteberg, J.
Weisshaar, D.
Verhoye, J. P.
Woo, Y. J.
Ha, R.
Haddad, F.
Banerjee, D.
2018
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University Medical
Center California
•2009-2015.

•RHF predicted 27%
using 2005 ASE
guideline & 37%
using RVLS or
TARPSE

STUDY 2
Prediction of Right
Ventricular Failure
after Ventricular
Assist Device
Implant:
Systematic Review
and Meta-Analysis
of Observational
Studies
Bellavia, D.
Iacovoni,
A.Scardulla, C.
Moja, L. Pilato,M.
Kushwaha, S.
Senni,M.
Clemenza, F.
Agnese, A. Falletta.
C.

•Compare
patients with early
post LVAD RVF with
patients
who did not
develop
acute RHF.
•Determine
prevalence
of post LVAD RHF
•Determine
significant
predictors for RHF
after
LVAD implantation

•36 of 612 studies
from a search
through OVID,
databases of
MEDLINE and
EMBASE,
Scopus,
Web of Science
and Google
Scholar from
•January 1, 1995April 30, 2015.
-35% prospective
cohort studies
-23% casecontrolled studies
-•995 of a pooled
4428 patients
referred for LVAD

•Retrospective
meta-analysis
•2 individual
reviewers
-> 18 years old
-No preplanned
RVAD
•Inclusion Criteria:
-Overt HF referred
for pulsatile or
continuous flow
LVAD
-RHF within 2
weeks post LVAD
•Data stratified for
-RHF and no RHF

•RHF defined as:
-Persistent RVSWI
<4g/m2 or
-NO > 48hrs or
-Emergent RVAD or
-Inotropes >2
weeks

•Determine if RV
load and RV
response to that
load are predictive
of risk for early RHF
and 6 month
mortality after CF
LVAD implantation
-Rv load =
pulmonary vascular
compliance (PC)i
-RV response =
CVP/PCWP

151 patients
•Inclusion:
-Complete preop
hemodynamic
measurements
•Exclusion:
-Planned RVAD
-Preop mechanical
support
•Single center,
Hospital of the
University
of Pennsylvania
•1/2008 - 6/2014.

•Retrospective
cohort
•Observational
•Longitudinal study
•Preoperative data
collected without
knowledge of the
outcome
•Patients stratified
into subgroups
based on PACi and
CVP:PCWP
-High PACi/low
CVP:PCWP

•RHF defined as:
-Unplanned RVAD
-Inotropes >14
days
-Death from RHF
within 14 days

•Significant
preoperative
predictors for RHF
after LVAD
-Demographic
-End organ
-Biomarkers
-Hemodynamic
-Echocardiographic

•Preoperative
predictors that
are significantly
different for RHF
post CF LVAD
compared to PF
LVAD

:•Significant
predictors of RVF:
-Lower BSA
-Female
-Preop IABP
-Preop mechanical
ventilation
-Preop RRT
-Higher WBC, TB,
ALT,AST
,INR,BUN,CR,proBN
P
-Lower plt ct
-Lower cardiac
index
,RVSWI,LVEDAI
-Higher PVR, PAS,
CVP, RVEDAI, RVLS
-Preop severe RVD
on echo

•Difficult to
compare
data and
generalize
from almost
exclusively
single centered
studies

•Prevalence:
-RHF (40.4%)
-Unplanned RVAD
(7.9%)
-Inotropes 14 days
(30.5%)
-RHF death <14
days(2.0%)
•Preop variables
common
to postop RHF
patients:
-Vasopressor
requirement

•Single center
•Retrospective
•Endpoints define
severe RVF only

2017

Pulsatile flow
LVADs no
longer used
•RVF definition
only
identify late or
severe RHF and
may miss
mild & moderate
RHF between mild
and severe
•Little explanation
for parameter
differences
between RVH
and no RHF
•Data collection,
RHF
diagnosis,
protocols
for RVAD
placement,
inotropes and NO
subjective among
providers, data
collectors
and centers

•Concluded that
parameters
currently
available reach
significance
yet have small effect
size & are
insufficient with to
identify RHF after
LVAD with
acceptable
accuracy
•Though not
significant,
parameters
consistently
trended in expected
directions

JBI 3b

•PACi/CVP:PCWP
quantifies risk
stratification for RHF
& mortality
-High PACi/low
CVP:PCWP = survival
(86%)
-Low PACi/high
CVP:PCWP= survival
(45%)
•Implies preop RV
reserve related to
RVD, critical to
determine of postop

JBI level 3c

STUDY 3
Right Ventricular
Response to
Pulsatile Load Is
Associated with
Early Right Heart
Failure and
Mortality After Left
Ventricular Assist
Device
Grandin,W.
Zamani, P.
Mazurek, J.
Troutman, G.

•Degree of risk
-PACi relationship
to CV/PCWP
(High,Low)
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•Survival at 6
months
•Preoperative
variables
associated with
post CF LVAD RHF
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Birati, E. Vorovich,
E. Chirinos,J.
Telford, R.
Marguilies, K.
Atluri, P. and Rame
J.

-Low PACi/low
CVP:PCWP
-High PACi/high
CVP:PCWP
-Low PACi/high
CVP:PCWP
•Patients followed
until death, heart
transplant or LVAD
explanation

2016

STUDY 4
Validation of
Clinical Scores
for Right
Ventricular
Failure
Prediction
After
Implantation
of Continuous
-Flow Left
Ventricular
Assist Device
Kalogeropoulos, A.
Kelkar, A.
Weinberer, J.
Morris, A.
Georgiopoulou, V.
Markham,D.
Butler,J. Vega
D.and Smith, A.

•Evaluate the
comparability
across
pre-existing
predictive models
using a unified
definition of RHF

•116 consecutive
patients
•Inclusion:
-Elective CF LVAD
-Heartmate II
-Heartware HVAD
-Bridge to
transplant
-Destination
therapy
•Exclusion:
-Unplanned RVAD
•Single center,
Emory University
Hospital
•1/2008 – 1/2013

•Retrospective
cohort
•Observational
•RHF risk scores
calculated:
-Michigan
-Penn
-Utah
-CRITT
•Unplanned
RVAD risk score
-Penn decision tree

-↑bilirubin
-↓ GFR
-↑ echo RV
dysfunction (RVD)
-↑CVP
-↑ CVP:PCWP
-↓PACi
•Independent
predictors of RHF
-↓ PACi with strong
association to echo
RVD
•PACi + CVP:PCWP
“modestly”
improved
discrimination for
early RHF
-Lowest risk = High
PACi/low CVP:PCWP
-Highest risk = Low
PACi/high
CVP:PCWP
•Death <6 mo.
(22.5%)
-↓GFR, ↑CVP,
↑CVP:PCWP,
↓PACi, ↓echo RVD
-PACi/CVP:PCWP
was significantly
associated
with 6 month
mortality
•RHF < 90 days
defines by:
->48h hours NO/
other pulmonary
vasodilators
- MSOF with
hypotension/
no sepsis
-Inotropes >14
days
-Inotropes
restarted
at >14 days
-Unplanned RVAD

•RHF < 90 days
defined by
INTERMACS:
-CVP >18
-CI <2.0
-No tamponade
-No ventricular
arrhythmia
-No pneumothorax
-Inotrope or
inhaled pulmonary
vasodilators >14
days
-Unplanned RVAD

2015

STUDY 5
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•RHF< 90 days
using the each RHF
definition:
•Expand sample to
include planned
RVAD
•Preop
parameters
significantly
correlated with
postop RHF

•Significant preop
predictors of RHF:
-Non-white race
-↓LV diameter
-↑ RAP or CVP
-↑ creatinine level
•The Michigan
score
performed best
-“modest”
discrimination
using either RHF
definition
-Predictive < 60%
accuracy

RHF risk.

•The models used
to calculate RHF
risk
intended
for risk of
requiring RVAD
•No rationale
for Michigan
performance
•CRITT & Pittsburg
decision tree only
scores derived
exclusively from
CF LVADs
•Bias toward >
destination LVADs

•Inclusion of preplanned RVAD may
have implications
for predictors of
high risk for early
/severe RHF
•Unique use of
MSOF/hypotension
has advantage of
no time limit
-May capture earlier
RHF or missed RHF
•Unique use of
inotrope restart may
capture late RHF
-Lead to ID of critical
events etiology
•Suggest change to
using quantitative
data since existing
scores moderately
discriminatory at
best
•Supports revising a
universal RHF
definition

JBI level 3c
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Right Ventricular
Failure in Patients
with the
HeartMate II
Continuous-Flow
Left Ventricular
Assist Device:
Incidence,
Risk Factors, and
Effect on Outcomes

•Evaluate
incidence, risk
factors, and effect
on outcomes of
RHF after
Heartmate II, CF
LVAD implantation

•484 patients
-Heart transplant
status 1A or 1B
- Heartmate II
LVAD
•36 centers
•3/2005-4/2008.

•Retrospective
cohort
•Observational
•Prospective data
collected during
multi-center
Heartmate II trial

↑RHF risk defined
by the Michigan
Risk score

•Early RHF after
defined by:
-Unplanned RVAD
-Inotropes >14
days
-Inotropes starting
> 14 days

Kormos, R.
Teuteberg, J.
Pagani, F. Russell,
S. John, R. Miller,
L. Massey, T.
Milano, C. Nader
Moazami, N.
Sundareswaran, K.
and Farrar, D.
2010

STUDY 6

74

•Outcome
associated
with of RHF at 180
days:
-Survival to
transplant
-Recovery
- support
-Actuarial Survival

•Met any criteria
for RHF (20%)
-Unplanned
RVAD(6%)
-Support >14 days
(7%) -Support
started > 14 days
(7%)support >14
days
•Variables
significantly
correlation to early
RHF, with greatest if
unplanned RVAD
-↑CVP( 15 + 7)
-↑ CVP/PCWP
(0.6+0.2)
-↓RVSWI( < 300 )
-↑WBC (10+4)
-↑ BUN
-Preoperative
ventilator
dependence
•Survival to
transplant, recovery
-No RHF (89%)
-Early RHF (71%)
-Unplanned RVAD
(67%) with 77% if
RVAD placed within
24 hours & 39% if
placed after 24
hours
•1 year actuarial
Survival:
-No RHF (79%)
-Unplanned RVAD
(59%)
-Inotropes >14 days
or started after 14
days (56%)
•Length of stay for
discharged patients:
-No RHF 21 days
- Unplanned RVAD
32 days for Inotrope >14 days
or started after 14
days 32-35 days

•Exclusive bridge
to transplant not
representative of
larger destination
population
•Exclusive to
Heartmate II
device
not representative
of other device
recipients
•Increased
correlation to
unplanned RVAD
implies values
predict highest
risk
and predictive of
severe/early heart
failure
-No distinction of
values correlated
to
milder RVD
different
than no RHF

•Implies variable
values may
correlated to risk
stratification in
future studies
•Supports concept
of preop and
declining RV
reserve; dynamic
risk

JBI level 3c
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Maximum
Vasoactive
Inotropic Score in
the 48 Hours PostLVAD Implantation
Correlates with
Early Severe Right
Ventricular Failure

Determine
correlation
between maximum
Vasoactive
Inotropic
Score (VIS) and
early RHF post
LVAD

•240 LVAD
recipients
•Exclusion:
- <18 years old
-LVAD exchange
-Planned RVAD
•Single center
•1/2006-12/2017

•Retrospective
cohort
-Stratified
maximum VIS
within 48 hours
postop
•Observational

VIS =
Dobutamine dose
+10 x Milrinone
dose +Dopamine
dose +100 x
Epinephrine
dose+100 x Neo
synephrine
dose+10,000 x
Vasopressin dose:
-6 hours
-24 hours
-48 hours

•RHF post CF LVAD
stratified by max
VIS in 48 hours:
-Group 1 (0-10)
-Group 2 (11-15)
-Group 3 (16-22)
-Group 4 (23-87)

Severe RHF
defined by:
-Inotropic support
> 14 days
-Unplanned RVAD
-RHF Death during
admission

Group 4 VIS (23-87):
-↑CVP
-Advanced
INTERMACS profile
-Older age
-Independently
correlated with post
LVAD severe RVF

•Single center
•Exclusion of
planned RVAD
may miss highest
risk for
comparative
values & defining
mild to moderate
RVD that could
progress as RV
reserve decreases
•Minimal
correlation with to
quantitative
measures of RV
which would have
greatly increased
value of study.

•Valuable in
capturing early
RHF that would
not have met
accepted
or modified
INTERMACS
definitions
previously and
more widely used
definitions of RHF.
•Offers a means of
tracking loss of RV
reserve and RVD
progression to RHF
postoperatively

JBI level 3c

•Develop "ALMA"
simplified risk
stratification
tool:
-To determine
tolerance of an
isolated LVAD vs.
Biventricular
support, “ALMA”
score

•258 patients
•LVAD cohort
(n=170)
--Derivation cohort
(n=135)
-Validation cohort
(n=35)
-unplanned
BiVAD(n=88)
-Derivation cohort
(n=71)
-Validation cohort
(n=7)
•Exclusion:
- <18 years old
-Artificial heart
•Coworker
Institutions, South
Ursula University
Hospital in Bologna
and S. Camillo
Hospital in Rome

•Retrospective
cohort
•Observational
•Compared
demographic,
echocardiographic
hemodynamic and
Laboratory
variables

Severe RHF <30
days defined
by:
-Unplanned RVAD
despite maximal
doses of inotropic
support and NO
inhalation

•Unplanned
RVAD
requirement
defined by:
-Interop failure to
wean off
cardiopulmonary
bypass pump
-Systemic low flow
(oliguria, low SVO2,
Lactate >2)
-CVP>18
-Low flowing LVAD
-Escalating NO or
inotropes with no
improvement

•All-cause
mortality

•Mean time
from LVAD
to RVAD
requirement
0-2 days
•LVAD & BiVAD
preop INTERMACS
profiles 2-3
•ALMA 5-point risk
score based on
parameters
predictive of
unplanned BiVAD:
-Destination
therapy
-PAPi <2
-RVSWi <300
-RV/LV ratio >0.75
-MELD-XI >17
•ALMA risk score
had satisfactory
predictive power for
RVAD

•May be limited
since it only
incorporated 5
parameters that
had opposing
significance in
previous and later
studies

•Supports
significance
of RV response
measured by size
and contractility,
to pulmonary
vascular load
•Supports RV
decompensation/
diminished
reserve by
inclusion of
MELD representing
end organ function.

JBI level 3c

•Investigate the
use of a Bayesian
statistical
risk
assessment
model
for RHF after LVAD
-176 preoperative
variables
considered
•Compare the
performance of the
Bayesian models to
previously
established and
widely used Risk

•10,909 adult
patients with CF
LVAD placement
included in the
data of the national
INTERMACS
registry
•December 2006March 2014

•Retrospective
cohorts
•Observational

•Acute RHF (<48
hours) defined by
INTERMACS
before 2014:
-33 variables
-Most predicted by
PAS, WBC, LVEF, CI,
Na,
% lymphocyte

•Early RHF (48
hours-14 days)
-34 variables
-most predicted by
PAS, pre-albumin,
LDH, INTERMACS
profile, RVEF, proBNP, age, HR, TR
and BMI

•Late RHF (>14
day)
-33 variables
-Mostly predicted
by peripheral
vascular resistance,
MELD score,
albumin,
%lymphocyte,
mean PAP, PAD

•The models for
acute, early and late
RHF had accuracy
levels of 91-97%
-out-performed
Mathews and
Drakos risk scores
•Variables most
predictive of Acute
RHF:
- PAS, WBC, LVEF,
CI, Na,%
lymphocyte
•Variables most
predictive of Early
RHF -PAS, pre-

•Undergoing a
current
prospective
evaluation with no
further publication

•Recognizes the
continuum of RV
dysfunction to
failure with dynamic
risk & possibly
distinct variable or
changing values of
variables
•Supports need to
consider
relationship
between variables
of pulmonary
vascular load, RV
size, RV contractility,

JBI level 3c

Kumar,S.
Mustehasan, M.
Chinnadurai, T.
Gupta, N. Patel, S.
Murphy, S. Shin, J.
Forest, S. Vukelic,
S. Golstein, D.
Jorde, U. and
Sims,D.
2020
STUDY 7
Calculation of
the ALMA Risk
of Right
Ventricular
Failure After
Left Ventricular
Assist Device
Implantation
LaForte, A.
Montalto, A.
Musumeci, F.
Amarelli, C.
Mariani, C. Polizzi,
V. Della, Monica,
P. Francesco
Grigioni, F. Di
Bartolomeo, R.and
Marinelli, G.
2018

STUDY 8
A Bayesian
Model to
Predict Right
Ventricular
Failure
Following
Left
Ventricular
Assist
Device
Therapy
Loghmanpour, N.
Kormos, R.
Kanwar, M.
Teuteberg, J.
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Murali,S. and
Antaki, J.
2016

scores
-Mathews RHF risk
score
-Drakos score

albumin, LDH,
INTERMACS profile,
RVEF, pro-BNP, age,
HR, TR and BMI
•Variables most
predictive of Late
RHF
-PVR, MELD score,
albumin,
%lymphocyte, mean
PAP, PAD

LV filling and end
organ perfusion

STUDY 9
Postoperative
right
ventricular failure
after left
ventricular assist
device placement
is predicted by
preoperative
echocardiographi
c structural,
hemodynamic,
and functional
parameters

•Compare
preoperative
variables
- RHF after LVAD
-No RHF
•Determine
variables with
significance for RHF
prediction
•Compare results
to Michigan, Penn,
BiVAD & MELD
scores

•55 patients
•Exclusion:
-No preoperative
TTE
-Poor RV images on
TTE
-LVAD no RHF
(n=26)
-LVAD with RHF
(n=16)
-Unplanned BIVAD
(n=13)
•Single center
•5/2008-6/2011

•Retrospective
cohort
•Observational
•Compared data
-LVAD with RHF
combined with
BIVAD to LVAD
no RHF

•Prolonged RHF
after
LVAD defined by:
-Inotropic support
>14 days
-Planned RVAD
-Severe pHTN,
-RAP or CVP > 15
-sustained with
hemodynamic
compromise

Variables
significantly
predictive of RHF
after LVAD

Raina, A. Seetha
Rammohan, H.
Gertz, Z. Rame,
E., Woo, Y. and
Kirkpatrick, J.
2013

STUDY 10
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•Significant
Predictive
preop variables:
-↑ BSA
-↓albumin
-↑with↑
inotropes/
vasopressors
-↓ INTERMACS
score
-↑heart rate
-Echocardiographic
↓RV FAC, LA
volume
index score
-Lower left atrial
volume
index score
•↑“echo score”
consisting of
combination of LA
volume index <38%,
(2pts),RV FAC <31%
(2pts) RAP >8 (2
pts).
-Echo score of >5
had 63% sensitivity
& 78% specificity for
predicting RHF
-Favorable in
comparison to
Michigan,
Pennsylvania and
MELD scores

•Identified 82%
with chronic heart
failure but no
mention of prehospital treatment
differences such
as continuous,
intravenous home
inotropic support
•No significance
difference in
RVEDAI between
RHF & no RHF
which may be
explained by
variations in
definitions &
inclusion criteria
•Single center
•Small sample size

•Though variables
differ findings
support
concepts of
pulmonary
vascular load, RV
response as most
significant factors
contributing to RHF.

JBI level 3c
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Risk Factors of
early Right
Implantation
with Intermediate
INTERMACS Profile
for Advanced Heart
Failure

•Identify predictive
parameters for
early post LVAD
RHF preop with
INTERMACS
intermediate
profile 3-5.

•80 of 214
consecutive
•Inclusion:
-INTERMAC Profile
3-5
-Bridge to
transplant
-Destination
therapy
•Exclusion:
ventilation
-Preoperative IABP
circulatory support
-Age <18
-Planned BIVAD
-Devices other than
CF LVAD
•2 centers, Thorax
and Cardiovascular
Surgery, Heart and
Diabetes Center,
Ruhr-University
Bochum, Bad
Oeynhausen,
German
an LVAD at the
between 20162018

•Retrospective
cohort
•Observational

•Early RHF after
defined by
INTERMACS
definition:
-CVP>16
-CI<2.3
-Insufficient LVAD
flow
-Echo evidence of
severe
RHF despite NO,
inotropic and
vasopressor
support and
intravascular
volume
optimization

•Preoperative
parameters
significantly
correlated with
early postoperative
RHF

•In hospital death

•Early RHF (32.5%)
•All in-hospital
mortality
organ failure or
systemic
infection
•Preoperative
parameters
predictive of early
RHF
-↑ CVP
-↑ CVP/PCWP
-↑RV dilation
-↑ RVEDAI/LV ratio
-↑severe TR
-↓RV FAC
-↑RVLS
•Preoperative
parameters that
were significant
independent
predictors of early
postoperative RHF
-CVP/PCWP>0.55
-BUN>44.5
-Combined these
values were related
to a 6.6-fold
increased risk of
early RHF

•Small sample and
•Single center
•Reported but did
not include
preoperative
inotropic support
or chronicity of
heart failure

•Would be
informative
to repeat with
comparisons
made to
INTERMACS profile
1-2
•Uniquely identified
optimized with
INTERMACS score 35 using PA catheter
parameters 24
hours before
surgery and echo
parameters within 5
days of surgery
which biased results
yet a valuable
comparison
•No time limits
included in RHF
definition less likely
to miss worsening
RVD & possibly
prevent RHF

•Evaluate preLVAD TTE
predictors
-Early RHF
-RHF death
•Determine
predictive value of
TTE variables after
adjusting for
Mathews RHF risk
score and Kormos
VIS score

•109 of 142
patients
•Exclusion:
-Poor TTE images
-RVAD placement

•Retrospective
cohort
•Data collected
prospectively
•Observational
•TTEs reviewed by
independent
readers blinded to
study data &
outcomes

•RHF within 30
days defined as
RHF within 30 days
defined as:
-Unplanned RVAD
-Inotropes >14
consecutive days

• RHF and death
within 30 days.

Mathews and
Kormos scores

•RHF within
30 days (23%)
•↓CI measured
across RVOT
-↑RV/LV diameter
ratio than no RHF
•RHF & death
within 30 days
•↑Mathews or
Kormos score =
↑RV/LV ratio
-↑Mathews&
Kormos
combined =
significantly
>risk of RHF & of
RHF
death within 30
days
• RV/LV more
consistent with
Mathews than
Kormos score
• RV/LV combined
with either score
increased
discrimination

•Small sample size
•Single center
•Exclusion of
RVADs eliminated
those with
greatest risk
•RHF defined by
time may lead to
missed diagnosis
or worsening RVD
prior to RHF

•Supports concept
of
preoperative RV
compensation and
added significance
with addition of
quantitative RV
parameters

Ruiz-Cano, M.
Morshuis, M.
Koster, A.
Lauenroth, V.
Prashovikj, E.
Gummert, J. and
PaluszKiewicz, L.

2020

STUDY 11
Increased Right
Ventricular
Diameter Ratio is a
String Predictor of
Right Ventricular
failure after Left
Ventricular Assist
Device
Vivo, R. CorderoReyes, A. Qamar,
U. Garikipati, S.
Trevino, A. Aldieiri,
M. Loebe, M.
Bruckner, B. TorreAmione, G.
Bhimaraj, A.
Tractenberg, B. and
Estep, J.

•Single centers,
Methodist
DeBakey Heart
& Vascular Center
•1/2004-7/2011

2013
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STUDY 12
Association of
Preoperative
Duration of
Inotropy on
Prevalence of
Right Ventricular
Failure Following
LVAD
Implantation

•Determine if
duration on
preop
Milrinone is an
independent
predictor of
post LVAD RHF

•104 patients
•Inclusion:
-ACC/AHA stage D
HF
-Continuous IV
Milrinone preop
-Heartmate II
-Heartware
-Bridge to
transplant
-Bridge to
candidacy
-destination
therapy
•Exclusion:
-Preop MSOF
-Preop mechanical
circulatory support
-Emergent LVAD
•Single center
•2/2012-10/2018

•Retrospective
cohort
•Observational
•Divided patient
into 2otherwise
similar groups:
-Milrinone <30
days (STM) n=55
-Milrinone >30
days (LTM)n=49

•RHF within 30
days defined as
RHF within 30 days
defined as:
-Unplanned RVAD
-Inotropes >14
consecutive days

•Survival through
follow-up
(27+26 months)

•Mortality
-RHF
-No RHF

•Total RHF (43.3%)
•Unplanned RVAD
-STM (9.1%)
-LTM (18.4%)
•Inotropes >14 days
-STM (16.4%)
-LMTM (44.9%)
•RHF significantly
>LTM
•Survival (74%)
-STM (27.3%)
-LMT (24.5%)
•Mortality:
-RHF (40%)
-No RHF (22.5%)
•Each preop day on
Milrinone correlates
with a 1% increased
risk of RHF postop.
•Quantitative RV
measures did not
reach predictive
significance

•Small sample size
•Single center
•Milrinone may
mask degree of RV
decompensation
which is
irreversible
without infusion

•Milrinone infusion
should be a
parameter
included in
preoperative
risk stratification
•May have
implications for
timing of LVAD
placement if results
are reproduceable
in a larger
population

JBI level 3c

•To determine if
quantitative
measure of RV
function is
predictive f RHF
after LVAD
-Global longitudinal
RV strain

•117 of 143
consecutive
patients
•Inclusion
-Heartmate II
-Heartware
•Exclusion
-Planned BiVAD,
RVAD, Total
artificial heart
-LVAD exchange
-Preop ECMO
-No or Poor TEE
•Single center,
Cleveland Clinic
Foundation
•5/2007-4/2011

•Retrospective
cohort
•Observational
•2 groups for
comparison
-RHF
-No RHF
•Retrospective
calculation
- Michigan score
-Global longitudinal
strain

•RHF defined by
-Unplanned RVAD
-Inotropic support
>14 days

•1 year mortality

•Preoperative
predictors of RHF

•RHF prevalence
(40%)
-Unplanned RVAD
(n=10)
-Inotrope > 14 days
(n=37)
•1 year Mortality
-RHF (19%)
-No RHF (19%)
•Preoperative
predictors of RHF:
-Inotropes
-↑bilirubin
-↓CI
-↑PVR
-Moderate RVD on
TEE
-Severe RVD on
echo
-RV free wall strain<
-9.6%
-RV longitudinal
strain was an
independent
predictor
•Michigan score +
qualitative RV
function vs
Michigan score+ RV
strain
-10.4% patients
with RHF would be
reclassified "at risk"
-Alone 67%
sensitivity & 76%
specificity

•Retrospective
calculation of RV
strain
•Single Center
•% patients with
insufficient echo
windows
•Time constrained
RHF definition
•Only used
Michigan score
which could have
influenced results

•Supports
evaluating
multiple variables
that interact to
comprise risk
•Supports use of
quantitative vs
qualitative RV
measurements
•Supports concept
of
preop RVD with less
reserve or further
on
the continuum of
progression to RHF

JBI level 3c

Benjamin, M. M.
Sundararajan, S.
Sulaiman, S.
Miles, B.
Walker, R. J.
Durham, L.
Kohmoto, T.
Joyce, D. L.
Ishizawar, D.
Gaglianello, N.
Mohammed, A.
2020
STUDY 13
Independent
and incremental
role of
quantitative
right
ventricular
evaluation
for the
prediction of
right ventricular
failure after left
ventricular assist
device
implantation
Grant, A. D. M.
Smedira, N. G.
Starling, R. C.
Marwick, T. H.
2012
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•Global longitudinal
RV strain
outperformed
TAPSE & RV:LV
diameter

STUDY 14
Timing and Trends
of Right Heart
Ventricular Assist
Device
Implantation
Gulati, G.
Sutaria, N.
Vest, A. R.
Denofrio, D. D.
KawaborI, M.
Couper, G.
Kiernan, M. S.
2020

•To determine the
optimal
timing of RAP
measurement
for prediction of
RHF post LVAD
•To determine
the significance
of resolution of
right heart
congestion prior
to LAVD

•134 of 144
consecutives
LVAD recipients
-INTERMACS
profile 2-3
•Exclusion:
-Preop ECMO
•Inclusion:
-Heartmate II
(n=86)
-Heartware 9n=45)
•Single Center,
Tufts Medical
Center
•10/2014-2/2018

•Retrospective
cohort
•Observational
•4 comparative
groups
-Congested
(RAP >14) at
admission that
improved before
LVAD
-Congested at
admission no
improvement
before LVAD
-No congestion
(RAP<14) at
admission or
before LVAD
-No congestion at
admission, new
congestion before
LVAD

•Unplanned
RVAD
•Death

supports

STUDY 15
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•Change in RAP
from admission to
<24 hours prior to
LVAD for grouping
•Significant other
variable differences
between groups

•Prevalence of RHF
(23%)
-Unplanned RVAD
(7.5%)
-Death (15.7%)
•
•No difference in
RHF between
congested & non
congested at admit
-Admit RAP not
associated with RHF
-No difference
between never
congested &
resolved
•>RVAD & death
rate for persistent &
newly congested
(80%) vs no
congestion (31%)
pre-LVAD
-No significant
difference in
persistent 7 newly
congested
-Persistent
congestion had
worse outcome
•prevalence of RHF
inclusive of
prolonged inotropes
(44%)
-78% on prolonged
inotropes

•Single center
•Small sample size
-reduced by
grouping
•Biased in a
center that admits
and aggressively
treats to
decongest
(RAP<10) before
LVAD
•Did not account
for patients
transferred from
& possibly treated
at outside hospital

•Supports concept
of RV reserve vs
irreversible or
advanced RVD in
continuum to RHF
•Supports concept
of using quantitative
vs qualitative RV
measurements
•supports concept
of dynamic vs one
pint in timer risk
assessment
-Registries do not
require record of
timing for
parameters
collected
-Most studies do not
specify timing of
parameters
collected or change
in parameters over
time

JBI level 3c
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Right ventricular
free wall
longitudinal strain
and stroke work
index for predicting
right heart failure
after left
ventricular assist
device therapy

•To examine new
parameters
associated with
post LVAD RHF
•To compare
performance of
new parameters
to existing
scoring systems

•57 consecutive
LVAD recipients
•Inclusion:
-Bridge to
transplant
-Heartmate II
(n=17)
-Heartware (n=28)
-Heartmate III
(n=8)
•Exclusion:
-Planned BiVAD
-Planned Total
artificial heart
•Single center
•1/2012-5/2018

•Retrospective
cohort
•Observational
•Comparison
groups
-RHF
-No RHF
•Hemodynamic
assessment
undefined timing,
OR and postop
•Echo 24-48 hours
before

•RHF defined by
INTERMACS:
-No tamponade
-MAP,55
-CVP>16
-CI<2.1
-Prolonged
inotropes (Inotrope
score 20)
-NO or IV
vasodilators>14
days
-Unplanned RVAD

•Calculated
Mathews,
Fitzpatrick, Drakes
and ARVASE scores
compared to
calculated scores
for heart failure
mortality not
specific for RHF
after LAVD
-Seattle Heart
Failure Model
-MELD score
-APACHE II
•Quantitative
measures of RV
-RVEF
-RV-FAC
-RVEDD
-RVSWI
-RVFWLS
-RVOT systolic
excursion

•Death
-5 months
-10 months
-15 months
-20 months
-25 months

•RHF prevalence
(35.1%)
-Unplanned RVAD
(n=11)
-Other criteria (n=9)
•Survival
significantly > in No
RHF group across all
intervals
•Existing scores
performed
modestly Fitzpatrick slightly
better than others
-HF mortality scores
performed > RHF
specific scores
-SHFM slightly
better
•Quantitative
parameters were
predictive of RHF
- RVFWLS, RVOT-SE
& RVSMI better
than others though
correlated with like
parameters
-RVFWLS most
discriminatory, 86%
sensitivity/845
specificity

•Small sample size
•Single center
•Did not combine
scores with
quantitative
variables for
further
comparison
though speak to
combining a
variety of
parameters
•Biased toward
majority of
INTERMACS
profile I &II
•Did not include
comparison to
qualitative RV
parameters most
used

•Very supportive of
incorporating newer
quantitative
measures
of RV function in risk
assessment
-Not included in
most
previously
developed
scores
•Supports concept
of measuring RV
function/reserve as
opposed to
size/volume status
alone
-Would need to be
incorporated into a
model of other
consistently
predictive
parameters to
assess increased
performance

JBI level 3c

•To review current
evidence for
preoperative
prediction ocf RHF
after LVAD
-Focus on imaging
& specifically echo

•Reviewed an
unspecified
number of studies:
-RHF prediction
models
-Quantitative
measures of RV
functio
-INTERMACS data

•Retrospective
review

•Identify rationale
for
inability to predict
post LVAD RHF
•To evaluate
quantitative
measures of RV
function and how
to best obtain data
•

•To evaluate
quantitative
measures of
RV function
and how to
best obtain
data

•To make
recommendations
for future inquiry
and practice

•Rationale for no
RHF
predictive model:
-Incidence
dependent varied
definition
-Single centers with
no
standard for RVAD
or Inotrope use
-No quantitative RV
data included in
existing models or
INTERMACS
-No accounting for
contributory interop
events
-Quickly changing
LVAD technology &
population
-No consensus on
how to best
measure RV
function
•Quantitative
Measures of RV:
-Measures of RV
strain & strain rate
best
-Standardize echo

•Did not speak
to other
hemodynamic
or laboratory
parameters
consistently
predictive
based which
could be
combined

•Recommendations
for standardization
would improve
practice but most
significantly value of
future
research/model
development
•Supports many
important concepts
to be incorporated
into risk models:
-RVD/RV reserve are
most predictive
-Quantitative RV
data
reproduceable/less
human error
-Risk for RHF can
increase at any
point along a
continuum
-Newer echo
technology negates
difficulty with RV
imaging especially
postoperatively to
allow serial
evaluation as
RVD/risk is dynamic

JBI level 3b

Gumus, F.
Durdu, M. S.
Cakici, M.
Kurklu, T. S. T.
Inan, M. B.
Dincer, I.
Sirlak, M.
Akar, A. R.
2019

STUDY 16
Assessment of
right ventricular
function in left
ventricular assist
device candidates
Hayek, S.
Sims, D. B.
Markham, D. W.
Butler, J.
Kalogeropoulos, A.
P.
2014
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protocols with
possible serial echo
-Expand & establish
a universal RHF
definition
-Revise INTERMACS
parameters &
definitions

STUDY 17
Pulmonary artery
pulsatility index
predicts right
ventricular failure
after left
ventricular assist
device
implantation
Kang, G.
Ha, R.
Banerjee, D.
2016

•Determine the
utility of PAPi in
prediction of
RHF or
unplanned RVAD
after LVAD
•To determine
if PAPi robust as
a predictive
independent of
preoperative
Inotrope
•To Determine if
timing of PAPi
measurement
changes predictive
value.

•83 of 85 LAVD
recipients
-Heartmat II (n=77)
-HeartWare (n-8)
•Single center,
Stanford university
Medical Center

•Retrospective
cohort
•Observational
•Blood work 24
hours prior
•PAPi 1-180 days
prior

•RHF defined by
INTERMACS:
-CVP>18
-CI<2.0
-PCWP<18
-Inotropic support
or NO
>7 days
•Unplanned RVAD
within 30 days

•PAPi <2
-On inotropes
-Off inotropes

STUDY 18

81

•PAPi
-> 12 days preop
- <12 days preop

•Unplanned RVAD
(n=9) significant
predictors:
-INTERMACS profile
1-2
-↑BUN
-↑RAP
-↓PAPi <2
-↑CVP/PCWP
-No other
parameters
including PVR
•RHF, no RVAD
(n=27))
-PAP independently
predictive
•Effect of inotropes
-PAPi more
predictive on
inotropes
-RAP unaffected
-CVP/PCWP less
predictive on
inotropes
•Timing of PAPi
-No effect on
predictive power

•Small sample
•Single center
•No accounting
for amount or
duration of
inotropes
•Minimal
explanation of
results related to
27 patients with
RHF vs. RVAD
•Timing may be
misleading as >12
days was a span
from 13-180 days

•Interesting index
which reflects after
& RV response more
accurately than PVR
or CVP/PCWP
individually
•Would be
interesting to track
for changes
which may
correspond to
critical events on
RVD-RHF continuum

JBI level 3c
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Preoperative threedimensional
echocardiography
to assess risk of
right ventricular
failure after left
ventricular assist
device surgery
Kiernan, M. S.
French, A. L.
Denofrio, D.
Parmar, Y. J.
Pham, D. T.
Kapur, N. K.
Pandian, N. G.
Patel, A. R.

•Determine the
association
between 3D
echo obtained
RVEF and RV
volumes (RVEDVI
RVESVI) with
post LVAD RHF
•Compare
predictive power
of2D & 3D echo
quantitative RV
parameters

•21 of 26 patients
•Inclusion:
-LVAD & BIVAD
recipients
with available
2D & 3D echo
data
-Heartmate II
(n=19)
-Heart Ware (n=5)
•Exclusion:
-Poor echo
images
•Single center,
Tufts Medical
Center
•1/2008-12/2011

•Retrospective
cohort
•Observational
•Grouped for
comparison
-RHF vs no RHF
- 2D vs 3D echo
parameters of size
& function

•RHF defined by:
-Inotrope > 14 days

•Predictive
hemodynamic
parameters of
-RAP
-CVP/PCWP
-CI
-PVR
-RVSWI

•Predictive echo
parameters
-2D RV/LV ratio,
RVFAC
-3D RVEF, RVESVI,
RVEDVI

•Prevalence of
Heart failure (46%)
-75%INTERMACS
profile 1 (75%),
-Profile 2-3 (33%)
•Predictive
Hemodynamics:
-↑CVP/PCWP
-↓RVSWI
-RAP trended ↑
-CO trended ↓
•Predictive 2D echo
parameters
-↑RV/LV diameters
- ↑RV-FAC
•Predictive 3D echo
parameters:
-↓RVEF
-↑RVESVI
-↑RVEDVI
•When influence of
RV hemodynamics
on RV volumes
adjusted, RVESVI &
RVEDVI remained
significant
predictors of RHF
-3D echo
parameters superior
to hemodynamic &
2D echo parameters

•Small size
•Single center
•No consideration
of preoperative
support or
definition of
"medically
optimized"
•No correlation to
end organ
perfusion
•No comparison
to RV strain
parameters which
have been found
predictive
-Definition of RHF
may have
influenced
prevalence &
results

•Made good case
for 3D echo
-Greater predictive
parameters
-No need for
contrast
-No contraindication
with pacemakers or
ICDs
-Technical ease of
obtaining
parameters pre &
postoperative
•Does support RV
size and function
and central
measurements for
prediction &
suggests
opportunities to
measure using
several different
parameters
•Interestingly also
found PVR
insignificant so may
be that it isn’t he
load but the RV's
response to the load
that is significant

JBI level 3c

•Evaluate
association
between 3D
echo
parameters
of RV
function and
RHF post LVAD
•Evaluate
previously
predictive
parameters

•26 of 77 LVAD
recipients
•Inclusion:
-Heartmate II
-Heartmate 3
-Heartware
-Median
Sternotomy
-"Less invasive"
placement
-"Few “Valve
repair/
replacement
•Single Center,
University of
Hospital Tubingen
•10/2013-7/2017

•Retrospective
cohort
•Observational
•Grouped for
comparison
-RHF vs no RHF
•All patients per
protocol:
-Milrinone started
before CPB pump -Dobutamine before
separation from
CPB pump
-No cardioplegia

•RHF defined by:
-Inotrope > 14 days
-Unplanned RVAD

•Previous
predictive
parameters

•Mortality by 3D
echo parameters
predictive of RHF

•Prevalence RHF
(19.2%)
-RHF no RVAD (n=3)
-Unplanned RVAD
(n=3)
•3D echo predictive
parameters
-RV LFWS- 10.1%
100% sensitivity
66.7% specificity
-RVEF
•Hemodynamic:
-CVP >15
40% sensitivity
42.9% specificity
-RV/LV diameter
>.75
60% sensitivity
47.6% specificity
•2D echo:
-RVLSFW
100% sensitivity
70% specificity
•Mortality:
-3D RVEF not
significant predictor
-3D RVFWLS
significant predictor
•Reclassification by
3D parameters

•Small sample
•Inclusion of full
sternotomy & less
invasive
•Inclusion of valve
surgery
•No comparison
groups who did
not follow same
protocol
•No account of
end organ
hypoperfusion
•No consideration
for timing of echo
or measurement
of other
parameters
•No consideration
of preoperative
inotropes/vasopre
ssors

•Study raises many
good questions for
future research
since the low
incidence of RHF
and
RVAD may be
explained by:
-Inotrope protocol
which may also
explain inconsistent
findings of
insignificance
of RVEDVI/RVESVI
-Minimally invasive
LVAD placement
-Correction of
valvular disease
•Significance of
RVEF & RVFWLS
support importance
of RV dysfunction
and response to LV
dysfunction
•All significant
parameters imply
the importance of
RV size and function
before further

JBI level 3c

2015

STUDY 19
3D Echocardiography
Derived
Right Ventricular
Function is
Associated with
Right Ventricular
Failure and Midterm Survival after
Left Ventricular
Assist Device
Implantation
Magunia, H.
Dietrich, C.
Langer, H. F.
Schibilsky, D.
Schlensak, C.
Rosenberger, P.
Nowak-Machen, M.
2018
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reclassified patients
who would have
been classified as
low risk by previous
parameters

challenge of LVAD &
OR events

STUDY 20
Pulmonary Artery
Pulsatility Index
(PAPi) is a
Predictor of
Right Ventricular
Assist Device
(RVAD) Use
Following
HeartMate 3
LVAD Implantation

•Determine if
PAPi is a
stronger
predictor of
RHF after
Heartmate 3
than CVP/PCWP
&RVSWI

•175 Heartmate 3
recipients
•Single center
•2014-2019

•Retrospective
cohort
•Observational

•Determine
predictive value
of ECG-gated
contrast enhanced
quantitative,
volumetric,

•12 of 67 LVAD
recipients
-GFR >40
-Functional CT
•Single center
•2016

•Retrospective
cohort
-Observational

•Other
parameters
associated with
RHF

Marshall, D.
Malick, A.
Truby, L.
Butler, C.
Griffin, J.
Clerkin, K.
Fried, J.
Raikhelkar, J.
Yuzefpolskaya, M.
Colombo, P.
Sayer, G.
Takayama, H.
Takeda, K.
Naka, Y.
Farr, M.
Uriel, N.
Topkara, V. K.

•Unplanned RVAD
(31.4%):
-Mostly INTERMACS
profile 1-2
-↑WBC
-↑C reactive
protein
-RVSWI no
significant
difference
-↑CVP/PCWP
significant predictor
-PAPi significant and
only independent
predictor

•Small sample
•Single center
•No information
regarding
preoperative
treatment
•RHF definition
limited to RVAD
most likely missed
all RHF diagnoses
-High RVAD
incidence may be
attributed to a
lower-thanaverage threshold
to place, no
criteria addressed

•Very limited yet
followed trends of
many other studies

JBI level 3c

•RHF prevalence
(58%)
•Significant
Predators
-REDVI
-RVEF

•Small sample
•Single center
•Ill-defined end
points making
results difficult to
interpret

•Though not
generalizable
findings follow
trend of other
studies
•Inclusion of GFR

JBI level 3c

2020
STUDY 21
Pre-LVAD CTDerived Measures
of RV Size and
Function May Be
Strong Identifiers
of Right Ventricular

•RHF as defined
by INTERMACS
criteria
-Undefined

•Functional CT
parameters
-RVEDVI
-RVEF
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•Other
parameters &
risk scores
previously
predictive
of RHF
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Failure
Scott, A.
Kim, P.
Adler, E.
Kligerman, S.
Tran, H.
Pretorius, V.
Contijoch, F.

functional
measures of RV
size and function
-RVEDVI
-RVEF

-CVP
-PAPi
-Creatinine
-Michigan score
-CRITT score

-PAPi
•No significant
prediction
-Michigan score
-CRITT score
-CVP

•Large bias GFR
>40

>40
implies minimally
available to a
population with a
high co-morbidity of
chronic kidney
disease & often
acute kidney injury
during states of
decompensated HF

•Survival at 2 years

•Prevalence of RHF
(72%):
-Mild (34%)
-Moderate (16%)
-Severe (13%)
-Severe Acute (9%)
•Parameters
significantly &
predictive of
severe/severe acute
RHF
-Ea which had
increased
discrimination if
coupled with RAP
•Survival at 2 years
-No RHF (72%)
-Mild-moderate
(71%)
-Severe-severe
acute
(55%)

•Retrospective
-High quality echo
uniformly
available
•Multicentered
-Multiple
operators
-Varied practices
which could
influence RV
function after
LVAD not
accounted for
-Varied/subjective
RAP
determination
with no
accounting for
accuracy based on
mechanism of
assessing

•One of the few
multicentered
studies with a
large population
•High prevalence
likely related to
unique use
INTERMACS
definition
-Broad definition of
increased RAP/CVP
with multiple
mechanisms of
confirming
-Added time limits
which indirectly
represented severity
to stratify and did
correlate to morality
however no direct
correlation cause of
death
•Use of Ea as a total
RV afterload
measure in
combination with
RV response
(RAP/CVP) supports
theme of RV reserve
as a predictor of
post RHF
-Though Ea +CVP
predictive of severesevere acute RHF,
2/3 did not progress
to RHF which may
have been
attributed to
interventions aimed
at preventing
progression.
Identification of
those interventions
or the critical events
that led to
progression would
truly support
dynamic risk
assessment and
clinical outcomes.

2020
STUDY 22
Pulmonary Arterial
Elastance and
INTERMACSDefined Right
Heart Failure
Following Left
Ventricular Assist
Device
Muslem, R.
Ong, C. S.
Tomashitis, B.
Schultz, J.
Ramu, B.
Craig, M. L.
Van Bakel, A. B.
Gilotra, N. A.
Sharma, K.
Hsu, S.
Whitman, G. J.
Leary, P. J.
Cogswell, R.
Lozonschi, L.
Houston, B. A.
Zijlstra, F.
Caliskan, K.
Bogers, Ajjc
Tedford, R. J.

•Determine if
INTERMACS
classification of
RHF predicts post
LVAD mortality
•Identify the
preoperative
parameters
predictive of
INTERMACS RHF
stages associated
with mortality

•375 LVAD
recipients
•Inclusion:
-Heartmate II
-Heartmate 3
-HeartWare
-Cardiac cath
within 30 days
before LVAD
-Median
sternotomy
•Multicenter
-Medical University
of South Carolina
(n=91)
-University of
Minnesota (n=166)
-Johns Hopkins
University School
of Medicine
(n=102)
-Erasmus Medical
center (n=16)
•2008-2016

•Retrospective
cohort
•Observational

•RHF defined by:
-Hemodynamic,
echo or clinical
signs of elevated
CVP
•Stratification of
RHF by severity:
-Mild=Inotropes
NO <7 days
-Moderated=
Inotrope/NO 7-14
days
-Severe=
Inotrope/NO >14
days
-Severe Acute=
unplanned RVAD or
RHF death

•Preop parameters
predictive power
for of severesevere Acute RHF
-CI
-RVEDP
-RV systolic
pressure
-PAS,PAD,Mean PA,
-PAPi
-PCWP
-Ea(PAS/SV)
-Creatinine
-Total bilirubin
-Hgb
-Platelet ct
-INTERMACS
profile

2019
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STUDY 23
Cardiac Passive
-Aggressive
Behavior? T
The Right
Ventricle
in Patients With a
Left Ventricular
Assist Device
Kimmaliardjuk, D.
M.
Ruel, M.
2017

•Describe
predictive
parameters for
post LVAD RHF
used in most cited
prediction models
•Identify other
independently
predictive
parameters
•Recommend RV
remediation
interventions

•219 of 526
PubMed
references
-"RHF after LVAD"
-"RV mechanical
support"
-limited to human
& English language

•Expert review:
-Literature scoping
-Systematic review

•Predictive
parameters
used in most
cited risk
assessment
scores
-Michigan
-Penn
-Utah
-Pittsburgh
Decision Tree
-CRITT
-Kormos
Multivariant
predictors

•Independently
predictive
parameters found
evidence literature
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•Preventive &
therapeutic
interventions
for RHF after LVAD

•No consensus on
predictive
parameters
•Modified
definitions
•Michigan Score:
-↑Vasopressors
-↑AST
-↑Bilirubin
-•Creatinine or
dialysis
•Penn
-↓CI
-↓RVSWI
-Severe RVD on
echo
-↑Creatinine
-↓SBP
-Previous cardiac
surgery
UTAH:
-↑PVR
-Preop IABP
-Destination
therapy
-Inotropes
-Obesity
-ACEi/ARB
-Beta-blocker
•Pittsburgh:
-Age
-TPG
-↑RAP
-↑INR
-↑HR
-↑ALT
-↑WBC
-# inotropes
•CRITT
-CVP > 15
-Severe RVD on
echo
-Severe TR on echo
-Mechanical
ventilation
-HR > 100
•Kormos:
-↑CVP/PCWP
-↓CI
-Mechanical
ventilation
-↑BUN
•Other parameters:
-RV longitudinal
strain
-RV FAC
-PAPi
-PACi
-Tethered TV
•Preventive
Interventions:

•Limited
discussion of
theme
/physiology which
relates all
variables
& interventions
•Lack of
discussion
regarding
preoperative
preventive
measures or
optimization
which could be
extracted from
review

•Viewing evidence
collectively explains
the risk factors in
related concepts
rather than
individual
parameters
or sets of
parameters
-Degree of RVD/RV
compensation &
reserve/end organ
reversible/irreversib
le dysfunction
assessed by RV size,
function and
changes in response
to pulmonary load,
liver & kidney
function define RHF
risk
•Viewing evidence
chronologically
defines the
parameters chosen
as they parallel
diagnostic
technology
-Increasing
capability of more
direct measures of
RV parameters are
progressively more
predictive than less
direct
•Identification of
intraoperative &
postoperative
preventive
measures imply
dynamically
changing degree of
risk and critical
events which can
change risk
throughout course
which can

JBI level 3b
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-↓CPB pump time
-Minimize
transfusions
-Full deairing
-Lower pump
speed/adequate LV
volume
-Minimize PVR with
low PEEP, no
hypoxia or acidosis
•Medical
treatment:
-Milrinone
- Inhaled NO
-IV/PO pulmonary
vasodilators
•Surgical treatment:
-ECMO
-RVAD
-TV repair
STUDY 24
Right Ventricular
Afterload
Sensitivity
Dramatically
Increases
After Left
Ventricular Assis
Device
Implantation: A
Multi-Center
Hemodynamic
Analysis

Houston, B.
Kalathiya, R. Hsu, S.
Loungani, R.
Davis,M. Coffin, S.
Haglund, N.
Maltais, S. Keebler,
M. Leary,P. Judge,
P. Steens, G.
Shah,A., Russell,S.
and Telford, R.

•Compare
hemodynamic
markers of RV
function &
afterload before
& after LVAD

•60 of 244
patients from 2
large centers
between 2005 &
2014
•Inclusion:
-LVAD via median
sternotomy on
cardiopulmonary
bypass pump
-Cath results at
each time interval
compete
•Exclusion Criteria
-On inotropes or
mechanical assist
preoperatively

•Retrospective
cohort
•Observational

•Hemodynamic
measures of:
-PVR
-Ea
-PACi
-PA pressures
-RAP
-RAP:PCWP
-CO

•Evidence of
ischemia

at:
-within 6 months
pre-LVAD
-0-6 months post
LVAD
-7-12 months post
LVAD
-13-18 months post
LVAD
-18-36 months post
LVAD

2020
STUDY 25
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•Survivorship

•PVR, Ea decreased
early postop
•PACi increased
postop
•RAP remained
high postop
•All parameters
improved in later
postop intervals
•No difference in
parameters
between
ischemic & nonischemic
•Non survivors had
higher RAP & RAP at
all time intervals

•Strict criteria
limited sample
size & generalizeability
•Long time
interval
attributed to high
attrition rate

•RV more sensitive
to afterload early
postop
•Decreased RV
reserve
implied by RAP
increases risk of
death after LVAD

JB level 3b

Risk of RHF After LVAD/MA Cyr

Right ventricular to
Left Ventricular
EndDiastolic Diameter
ratio and
Prediction of Right
Heart Failure with
Continuous Flow
Left Ventricular
Assist Devices

•To determine if
RHF after LVAD
could be predicted
by RV/LV ratio

•115 consecutive
patients preselected for LVAD
& 22 for BIVAD
between 2007 &
2009 at a single
center

•Retrospective
cohort
•Observation

•RHF defined by
-MAP <55
-RAP > 16
-CI <2
-SVO2 > 55%
-Inotropic
support score
-Need for RVAD

•RV/LV ratio

•RHF defined by
-Inotropes
required > 14
days after LVAD

•RV function by
TEE
-RV FAC
-RVLS
-RVGS
-S'
-TAPSE

•30 day mortality

•↑RV/LV ratio
significant predictor
of RHF after LVAD
•↑RV/LV ratio
associated with
30 day mortality

•Definition of RHF
and criteria for
RVAD
center specific
•Small sample size

•RV/LV is an easily
obtainable
parameter
which may be
capable
of demonstrating
external validity
•Coupling
parameters
supports the
significance of RV
reserve in risk for
RHF

JB level 3b

•Center specific
RVAD RHF and
criteria and
limited
generalizability

•RV function before
LVAD is a predictor
of RHF as all
measures
trended toward RHF
after LVAD

JB level 3b

•Exclusion criteria
-Acute CHF
-Post cardiotomy
heart failure

Kukucka, M.
Steponenko, A.
Potapore, E.
Knobatsch, T.
Redlin, M.
Mladenow, A.
Kuppe, H. Hetzer,
R. and Habazetti,
H.

2020
STUDY 26
Intraoperative
Transesophageal
Echocardiograph
and Right
Ventricular Assist
Device
Implantation

•To determine
whether interop
measures of RV
function are
associated with
RHF after LVAD

•100 patients
at a single center
undergoing
elective LVAD

•Retrospective
cohort
•Observational

•Need for
unplanned RVAD

•Only RV FAC
showed
a significant
association to RHF
after LVAD

•Supports the lack
of consensus for
which parameters
are
best as RV FAC has
been an inconsistent
predictor of post
LVAD RHF

Silverton, W. Patel,
R. Zimmerman, J.
Ma J. Stoddard, G.
Selzman, C.
Morrissey, C.

2021
STUDY 27
Intraoperative
Hemodynamic and
Echocardiographic
Measures
Associated with
Severe Right
Ventricular Failure
after Left
Ventricular Assis
Device
Implantation

Gudejko.M.
Gebhardtm B.

Evaluate if interop
parameters
differed
between patients
with severe RHF
and no severe
RHF after LVAD
•CVP & PAPi
•Quantitative TEE
measurements

•81 of 100 patients
from 2013-2016
•Inclusion criteria:
-HM II or HVAD
-Prop inotropes
•Exclusion criteria:
-Missing data
-Additional cardiac
procedures in OR
-Left OR with open
chest
-RVAD with LVAD

•Retrospective
cohort
•Chart
review
•Two comparison
groups
-Severe postop RHF
-Non severe postop
RHF

•INTERMACS
criteria:
- RVAD
-Inotropes or
pulmonary
vasodilator
>14 days

•Calculated
Mathews,
Fitzpatrick, Drakes
and ARVASE scores
compared to
calculated scores
for heart failure
mortality not
specific for RHF
after LAVD
-Seattle Heart
Failure Model
-MELD score
-APACHE II
•Quantitative
measures of RV
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•Quantitative
echo:
-TAPSE
-RV FAC

•CVP and PAPi
showed
discrimination for
severe RHF

•Hemodynamic
-CVP
-PAPi

•TEE TASPE & RV
FAC
had some
consistency

•Clinical factors
•Michigan score did
not differ between
severe & nonsevere
RHF
•Larger volume &

•Small sample size
•Single center
•No protocol for
RVAD placement
or
inotropic/
pulmonary
vasodilator
treatment

•Intraoperative
events
contribute to risk for
RHF
•Previous risk scores
are not reliable for
clinical prediction of
risk for RHF

JB level 3b
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Zahedi, F. Jain, A.
Breeze, J.
Lawrence,M.
Sherman, S. Kapur,
N. Kiernan, M.
Couper, G. and
Cobey, F.

-RVEF
-RV-FAC
-RVEDD
-RVS

blood resuscitation
in OR associated
with risk
for severe RHF

2020
STUDY 28
High Pulmonary
Vascular
Resistance In
Addition to Low
Right Ventricular
Stroke Work
Index Effectively
Predicts Biventricular Assist
Device
Requirement.,
Immamura, T.
Kinugawa, K,
Kinoshita, O.
Nowata, K.
andOno, M.

•To assess
significance of
RVSWI and PVR
for BIVAD
requirement

•116 patients at
a single center
between 20032015
-All device
e types
included

•Retrospective
cohort
•Observational

•RVSWI and
PVR
•Four groups
-RVSWI <5 & PVR
<3.7
-RVSWI >5 & PVR
<3.7
-RVSWI >5 & PVR
>3.7
=RVSWI <5 & PVR
>3.7

•Need for RVAD

•INTERMACS
profile

•RVSWI <5 coupled
with PVR. 3.7 an
independent
predictor of need
for RVAD

•Minimal
generalizeability related to:
-Redefined
INTERMACS
profiles
-Center specific
RVAD criteria
-Many types of
devices included

•Decreased RV
reserve implied by
RVSWI <5 & PVR
>3.7 predicts
need for RVAD
which implies
severe RHF

JB level 3b

•To assess
predictors of
RHF focusing
on clinical
manifestations

•112 patients of
132 undergoing
emergent or
elective LVAD at a
single center
between 20092017
•Inclusion criteria
-> 18 years old
-continuous flow
device insertion
•Exclusion criteria
-Preop
hemodialysis
-Planned RVAD

•Retrospective
cohort
- Chart review
-Observational

•RHF defined by:
-CVP > 16 with
no JVD or
respiratory
variation
-> 2+ peripheral
edema
-Ascites
-Hepatomegaly
-Total bili >2
-Creatinine >2

•Early RHF
-7 days postop
-14 days postop

•Late RHF
-1 month postop
-3 months postop
-6 months postop
-12months postop

•73 cases (64.3%)
with
preop RHF
->CVP/PCWP & CVP
- < load adaptability
index
-Lower INTERMACs
profile
- No difference in
echo

•Retrospective
•Small sample size
•Single center
•Exclusion of
preop Hd and
planned RVAD
-criteria institution
specific & may
have changed over
years reviewed
-highest risk
exclusion may
skew
findings &
predictive
parameters
•Very limited
definition of RHF
may have
underestimated
pre & postop RH
-No accounting for
required medical
or mechanical
support

•Supports concept
of
decreased RV
reserve
as a primary risk
factor as
parameters such as
CVP/PCWP
combined with load
adaptability index
define reserve as
opposed to
function.
•Delineation of
early, persistent late
& new onset late
supports the need
for early recognition
of risk for RHF if
worst outcomes are
to be prevented.

JB level 3b

2016
STUDY 29
Right Heart Failure
Before LVAD
Implantation
Predicts Right
Heart Failure After
LVAD Implantationis it that easy?

Wagner, T.
,Bernhardt, A.,
Magnussen, C.,
Reichenspurner, H.,
Balkenberg, S., and
Grahn, H.

•Early RHF
-Significant
association
with preop RHF
- significantly <
survival
at 14 days than no
RHF
or late RHF
-preop > CVP/PCWP
--<load adaptability
index
- <Hgb
-<INTERMACS
profile
-Younger

2020
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•Late RHF
-50% Persistent,
50% new onset
-Survival equivalent
with early RHF after
30 days
-Preop RHF not
associated with new
onset late RHF
•Best predictors of
early & persistent
late RHF
-↑CVP/PCWP
-↓load adaptability
index
-↑BUN/CR
-lower INTERMACS
profile
-younger age•
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Appendix C
SWOT Analysis for Institution of Implementation
Strengths
▪
▪
▪
▪
▪
▪
▪
▪
▪

Weaknesses
▪
▪

Commitment to providing advanced
technology, innovation & multidisciplinary care
to patients with severe heart failure
Employment of physicians with heart failure
specialty certification
Designated heart failure and ICU APRNs who
coordinator care across the continuum of care.
Standard preoperative work up for all Hartford
Hospital CF LVAD candidates
Employment of a dedicated CF LVAD data
manager
Participation of a national registry for outcome
measurement & comparison.
Well established forums for multidisciplinary
communication regarding CF LVAD
candidates & recipients
Availability of state-of-the-art diagnostic and
therapeutic technology
Well support for staff education and
maintenance of competency

▪
▪
▪
▪
▪

Opportunities
▪
▪
▪
▪

▪

Exclusion of quantitative RV parameters
Exclusion of specific right heart failure (RHF)
risk assessment from care planning
discussions
Exclusion of RV specific parameters from data
collection and analysis
Acceptance of RHF which may
underestimated outcomes based on
incomplete data input.
Lack of standardized care pathway for patients
with increased risk for RHF
Variable knowledge levels of care providers
across phases of care regarding RHF
Need for complex coordination of care across
providers in several departments and
specialties within the heart & vascular institute

Threats
▪

Ranked America’s top 50 hospitals for cardiac
care.
A large referral base from a centrally located
main campus and multiple satellite locations
across two states
Physicians are nationally connected allowing
sharing of data & collaboration across many
systems
National recognition of the complex needs of
heart failure patients with establishment of a
physician specialty education and certification
in 2010.
Growing population of heart failure patients
managed with CF LVAD implantation with
indication expanded to bridge to decision for
heart transplant candidacy and destination

▪
▪

▪
▪
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A trend toward higher risk and greater number
of candidates for CF LVAD:
-Expanding indications for use
-Availability temporary life-saving technology
which serve as bridge to CF LVAD
National registry’s exclusion of quantitative,
RV specific data for RHF prediction &
diagnosis
Rapid advancement of available diagnostic
and CF LVAD technology challenging timely
and applicable research and caregiver
competence
Rising cost of providing diagnostic and
mechanical replacement technology
Lack of evidence for parameters proven to
reliably predict RHF after CF LVAD
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Appendix D
Figure 16
Project Timeline/Gantt Chart
PREDICTING RIGHT HEART FAILURE FOLLOWING IMPLANTATION OF A CONSTINUOUS FLOW LEFT VENTRICULAR
ASSIST DEVICE

Gantt Chart
Healthcare System: Hartford Healthcare
Operational Leader: Mary-Ann Cyr MSN APRN ACNP
Project Timeline: May – December 2021

Task

Sub-task

Adapted from https://www.vertex42.com

Task

Assigned
To

Start Finish Progress
Date Date

Assemble project team

Project leader

5/1

8/20

50%

Complete proposal &
present to nursing
research council and IRB
portocol
Develop preliminary
assessment tool

Project leader

8/1

8/19

100%

Project leader
project
manager,
project
sponsor
Project leader

6/1

6/14

100%

8/14

8/14

0%

•

Project leader

8/16

8/26

0%

•

Email Expert review form
and RHF risk assessment
draft
Meet with Heart Failure
experts

May
Week
1 23
4

June
July
Week
Week
1 2 3 1 2 3
4
4
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August September October
Week
Week
Week
12 3 4 1 2 3 4 1 2 3
4

November
Week
1 2 3 4

December
Week
1 2 3 4

Risk of RHF After LVAD/MA Cyr
Meet with cardiac
anesthesiologist/surgeon
experts
Meet with Internal ICU
experts

Project leader

8/16

8/26

0%

•

Project leader

8/16

8/26

0%

•
•

Project leader

8/20

8/30

0%

•

Project leader

7/6

8/15

100%

•

Project leader,
Project
manager, Data
manager
Project leader,
project
manager,
project
sponsor
Project team
members

7/16

8/4

100%

•

9/8

9/8

0%

9/9

12/17

0%

Calculate RHF risk score
during each phase of
care for each patient
undergoing LVAD
implantation

Project leader

9/16

12/23

Attend weekly
multidisciplinary patient
rounds
Review monthly registry
outcome reports

Project leader,
Project
manager
Project leader,
project
manager, data
manager
Project team
members

9/16

12/17

0%

10/1

12/17

0%

12/10

12/23

0%

Finalize tool with project
manager & project
sponsor
Complete proposal &
present to HHC Nursing
Research& IRB
Develop data
management plan

Team kick off meeting

Weekly communication
with representatives to
update progress&
receive feedback

closing/distribution of
user survey/Analysis of
results/planning
project’s future
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Appendix E
Expert Panel Invitations
Institution of Implementation
Heart Failure Certified Physician, Critical Care Intensivist, Critical Care APRN
National: Tufts Medical Center, Mayo Clinic, Massachusetts General Hospital, Yale-New Haven
Hospital, Cleveland Clinic
Heart Failure Certified Physicians, Critical Care Advanced Practice Registered Nurses, and Physician
Assitants
International
Antonio LoForte MD, Developer of ALMA Right Heart Failure Risk Score
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Appendix F
Expert Panel’s Instructions
Dear Expert,
This review contains parameters related to evaluation of the right heart for patients undergoing LVAD placement.
I am seeking your objective expert judgement on the relevance and accuracy of measures which are supported by the
evidence for each parameter.
My DNP project aims to adapt, implement and evaluate a right heart failure risk assessment instrument for LVAD
candidates and recipients. Your review will be helpful in the final selection of measures to be included in the risk
assessment.
I included a reference table with definitions for each measure. It would be helpful if you use this reference to
make judgements on parameters you currently use and those which you do not use in practice. You can make any
further comments or recommendations concerning measurement of each parameter in the space provided.

94

Risk of RHF After LVAD/MA Cyr

Appendix G
Expert Relevance Rating Instrument

Relevance Rating Scale
1 = Measurement not relevant to parameter

3 = Measurement is quite relevant to parameter

2 = Measurement is somewhat relevant to parameter

4 = Measurement is highly relevant to parameter

Please relevance of measurements to the corresponding parameter using the scale below.
Measurements
PAPi
PACi
Ea
Measurements
CVP or RAP
CVP : PCWP
Echocardiographic
RV : LV Diameter
RVEVDI : LVEDVI
RVEDAI : RVEDVI
RVLS
RVEF
RVSWI

Parameter: PULMONARY HYPERTENSION
Relevance
Recommendations/Comments
1 2 3 4
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
Parameter: RV COMPENSATION FOR PULMONARY HYPERTENSION
Relevance
Recommendations/Comments
1 2 3 4
⃝⃝⃝⃝
⃝⃝⃝⃝

⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
Parameter: RV DECOMPENSATION
Measurements
Relevance
Recommendations/Comments
1 2 3 4
MELD
⃝⃝⃝⃝
Creatinine
⃝⃝⃝⃝
4
=
Measurement
is
highly
relevant
Lactate
⃝ ⃝ to
⃝parameter
⃝
Inotrope Requirement
⃝⃝⃝⃝
Vasopressor Requirement ⃝ ⃝ ⃝ ⃝
IABP Requirement
⃝⃝⃝⃝
RVAD Requirement
⃝⃝⃝⃝
ECMO Requirement
⃝⃝⃝⃝
Mechanical Ventilation
Requirement
⃝⃝⃝⃝
Renal Replacement
Requirement
⃝⃝⃝⃝
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Appendix H
Expert Accuracy Rating Instrument

Please rate the following measurements for their accuracy in measuring the corresponding
parameter using the scale below.
Accuracy Rating Scale
1 = Not an accurate measurement of parameter

2 = Somewhat accurate measurement of parameter

3 =Quite accurate measurement of parameter

4 = Highly accurate measurement of parameter

Measurements
PAPi
PACi
Ea
Measurements
CVP or RAP
CVP : PCWP
Echocardiographic RV : LV
Diameter
RVEVDI : LVEDVI
RVEDAI : RVEDVI
Measurements
RVLS
RVEF
RVSWI
Measurements
MELD
Creatinine
Lactate

Parameter: PULMONARY HYPERTENSION
Accuracy
Recommendations/Comments
1 2 3 4
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
Parameter: RV DILATION
Accuracy
Recommendations/Comments
1 2 3 4
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
Parameter: RV CONTRACTLITY
Accuracy
Recommendations/Comments
1 2 3 4
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
Parameter: END ORGAN PERFUSION
Relevance
Recommendations/Comments
1 2 3 4
⃝⃝⃝⃝
⃝⃝⃝⃝
⃝⃝⃝⃝
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Appendix I
Evaluation of Expert Panel Responses Instrument
Domain

Relevance
Ratings

Accuracy
Ratings

Relevance
Mean

Pulmonary Hypertension
PAPi
PACi
Ea
Compensation
RV Dilation
CVP/RAP
CVP/PCWP
RVEDVI
RVEDAI
RVEVDI/LVEDVI
RVEDAI/RVEDVI
RV Contractility
RVLS
RVEF
RVSWI
Decompensation
End-organ perfusion
MELD
Creatinine
Lactate
Medical support
Inotropic Infusion
Vasopressor Infusion
Mechanical Support
IABP
Temporary RVAD
Temporary LVAD
Mechanical Ventilation
Renal Replacement
ECMO
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Appendix J
Power Point: Project Introduction
Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation
Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation
Mary-Ann Cyr MSN APRN ACNP
Doctorate of Nursing Practice Candidate, Yale School of Nursing
APRN Cardiothoracic Surgery, Bliss 9ICU

Background

The Purpose
▪ Right heart failure is the primary cause of
morbidity and mortality after placement of a
continuous flow left ventricular assist device
(LVAD).

▪ Lack of a comprehensive tool for reliably
assessing impending right heart failure has
resulted in failure to recognize risk and
progression to right heart failure for LVAD
recipients.

July,14, 2021

The Population

▪ Combining RHF risk predictors is more reliable than
using individual parameters

▪ Risk varies throughout the perioperative phases of care

Jessica Coviello DNP, APRN, ANP-BC
Yale School of Nursing
Academic Advisor

Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation

The Evidence

Implies a dynamic assessment of risk for RHF
throughout the preoperative, intraoperative and
postoperative phases of care

▪ A convenience sample of LVAD candidates
and recipients referred to the Center for
Advanced Heart Failure for LVAD evaluation
and implantation from September 2021December 2021.

▪ To encourage use of an evidence based
RHF risk score by providers

▪ To positively impact outcomes for LVAD
recipients.

➢ Average of 40 patients referred
annually 2019-2020
➢ 33 patients referred January-May 2021

➢ Average of 15 LVADs implanted
annually 2018-2020
➢ 45 currently active LVADs
Confidential and Proprietary Information

Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation

April 15, 2022

Can risk for RHF after LVAD be determined by use
of a RHF risk score calculated preoperatively,
intraoperatively and postoperatively?

▪ Implement and evaluate the RHF risk assessment tool for
LVAD candidates and recipients referred to Hartford
Healthcare

Parameters
Pulmonary Hypertension
PAPi (PAS-PAD/CVP)
Ea (PAS/SV)
RV Dilation
CVP
CVP/PCWP
LV/RV end diastolic diameter
RV Contractility
RVLS
RVEF
RVSWI
End Organ Perfusion
CVVH,HD
MELD
Creatinine
Medical Support
IV vasopressor or inotropic medication infusion
Mechanical Support
Mechanical ventilatory support
Mechanical circulatory support > LVAD

The RHF Risk Assessment Tool

▪ Make recommendations for repeating and expanding
use of the RHF assessment tool based on findings

Total Score:

July 16, 2021

5

Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation

April 15, 2022

4

Table 3: Adapted RHF Risk Assessment Tool

▪ Disseminate project finding through publication and
presentation.

Confidential and Proprietary Information
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Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation

The Aims
▪ Adapt a tool for assessing risk for RHF associated with LVAD
implantation
The Project Question

3

Confidential and Proprietary Information

July 16, 2021

Score = 1
PAPi <2.0 OR Ea 1.16

CVP > 16 OR CVP:PCWP>.50 OR LV/RV >.75

RVLS

OR RVEF

OR RVSWi >300

MELD >17 OR Creatinine >2 OR New

>1 medication
Mechanical Ventilator Dependence
IABP OR RVAD OR ECMO

4-6 Highest risk

2-4 Intermediate risk

0-2 Lowest risk
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Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation

Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation
Project Owner/Operational Leader
Mary-Ann Cyr APRN, Bliss 9I
Doctor of Nursing Practice Candidate
Yale School of Nursing

The Theoretical Framework

The Method

Project Manager
Nicole Huhn APRN
Team Leader
Mechanical Circulatory Support Program

▪ Adapt the ALMA RHF risk
score.

▪ Introduction during weekly
multidisciplinary team meeting

▪ Evaluate providers’ perception

Project Sponsor

“Knowledge to Action”

The Stakeholder
Team

Abhishek Jaiswal MD
Associate Director
Mechanical Circulatory Support Program

Data Collection
Colleen Drake MS, RDCS
Heart Failure Analytics & Administrative
Coordinator

Incorporate RHF risk score into
multidisciplinary presentation and
evaluations of LVAD candidates &
recipients for three-months

Expert panel review

Provider Representatives

▪ Analyze risk parameters &
scores

To be determined

The project has been discussed and approved by:
Jason Gluck MD
Deborah LaMarr APRN
Randolph Edwards MD
Confidential and Proprietary Information

July 16, 2021
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Director, Mechanical Circulatory Support Program
Advanced Provider Manager, Cardiothoracic Surgery Team
ICU Medical Director, Hartford Hospital

Development

Assessing Risk for Right Heart Failure Following Continuous
Flow Left Ventricular Assist Device Implantation
Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation

Implementation

Confidential and Proprietary Information
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July 16, 2021

Evaluation
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Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation

The following parameters already collected will be provided to the project owner
The project owner will reorganize parameters into a risk score

Clinical Impact

Providers’ Perception

Demographic Data

▪ Share a Zoom recording of the power point presentation or
arrange for live presentation by the Operational Leader.
Representatives Responsibilities

charting and sign-off locations within their respective

departments.
▪ Facilitate documentation of tool parameters in the electronic
record appropriate for the phase of care.
▪ Facilitate calculation and incorporation of the adapted RHF risk
score into patient presentations, hand-offs, and care planning.
▪ Collect and provide prospective feedback during weekly email
communication with the Operational Leader.
Confidential and Proprietary Information
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Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation

“ Most Trusted for Personalized Coordinated Care.”

Parameters of RV Contractility
*Data will be stored on Hartford Hospital computers in a
stored in password protected file and will not be stored on
removable media.

RVLS
RVEF
RVSWI

*Each patient will be assigned a unique ID. A data sheet
linking the patient to the data will be maintained in a
separate file with only the PI having access. No one not
affiliated with the project will have access to the data.

▪ Begin to establish an evidence-based standard of care for patients undergoing LVAD implantation

MELD
Creatinine

Parameters of Medical Support
IV vasopressor or inotropic medication infusion

Parameters of Mechanical Support
Mechanical ventilatory support
Mechanical circulatory support > LVAD

Confidential and Proprietary Information
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Assessing Risk for Right Heart Failure Following Continuous Flow Left
Ventricular Assist Device Implantation
Ali, H. R., Kiernan, M. S., Choudhary, G., Levine, D. J., Sodha, N. R., Ehsan, A., & Yousefzai, R. (2020). Right Ventricular Failure Post-Implantation of Left Ventricular
Assist Device: Prevalence, Pathophysiology, and Predictors. ASAIO Journal, 66(6), 610-619. https://doi.org/https://dx.doi.org/10.1097/MAT.0000000000001088
Graham, I. D., Logan, J., Harrison, M. B., Straus, S. E., Tetroe, J., Caswell, W., & Robinson, N. (2006). Lost in knowledge translation: time for a map? J Contin Educ Health Prof,
26(1), 13-24. https://doi.org/10.1002/chp.47

Hayek, S., Sims, D. B., Markham, D. W., Butler, J., & Kalogeropoulos, A. P. (2014). Assessment of right ventricular function in left ventricular assist device candidates.
Circulation:Cardiovascular Imaging, 7(2), 379-389. https://doi.org/10.1161/CIRCIMAGING.113.001127
Houston, B. A., Kalathiya, R. J., Hsu, S., Loungani, R., Davis, M. E., Coffin, S. T., Haglund, N., Maltais, S., Keebler, M. E., Leary, P. J., Judge, D.P., Stevens, G. R.,
Rickard, J., Sciortino, C. M., Whitman, G. J.,Shah, A. S., Russell, S. D., & Tedford, R. J. (2016). Right ventricular afterload sensitivity dramatically increases after
left ventricular assist device implantation: A multi-center hemodynamic analysis. Journal of Heart and Lung Transplantation, 35(7), 868-876.
https://doi.org/10.1016/j.healun.2016.01.1225

Loforte, A., Montalto, A., Musumeci, F., Amarelli, C., Mariani, C., Polizzi, V., Lilla Della Monica, P., Grigioni, F., Di Bartolomeo, R., & Marinelli, G. (2018). Calculation of the
ALMA Risk of Right Ventricular Failure After Left Ventricular Assist Device Implantation. ASAIO Journal, 64(6), e140-e147.
https://doi.org/https://dx.doi.org/10.1097/MAT.0000000000000800
Rao, S. D., Adusumalli, S., & Mazurek, J. A. (2020). Pulmonary Hypertension in Heart Failure Patients. Card Fail Rev, 6, e05. https://doi.org/10.15420/cfr.2019.09

▪ Enhance HHC system’s delivery of value-based care
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Deidentified parameters
Project owner calculation

Optional Redcap Survey using
coded responses for:
Usefulness
Feasibility
Impact on Clinical Decision Making

Lampert, B. C., & Teuteberg, J. J. (2015). Right ventricular failure after left ventricular assist devices. Journal of Heart and Lung Transplantation, 34(9), 1123-1130,
Article 6055. https://doi.org/10.1016/j.healun.2015.06.015

▪ Improve clinical, financial, and quality of life outcomes for this population of patients within the Hartford Healthcare
System.

RHF Risk Score
Calculation

Providers’ Evaluation

Parameters of End Organ Perfusion

*Statistical analysis of demographic data, parameters &
scores will be conducted by Hartford Hospital Research
Statisticians.

Confidential and Proprietary Information

July 16, 2021

CMA1

Use in Practice
Documenting parameters
Calculating RHF risk score
Incorporating RHF risk score

Gudejko, M. D., Gebhardt, B. R., Zahedi, F., Jain, A., Breeze, J. L., Lawrence, M. R., Shernan, S. K., Kapur, N. K., Kiernan, M. S., Couper, G., & Cobey, F. C. (2019).
Intraoperative Hemodynamic and Echocardiographic Measurements Associated With Severe Right Ventricular Failure After Left Ventricular Assist Device
Implantation. Anesthesia and analgesia, 128(1), 25-32. https://doi.org/10.1213/ANE.0000000000003538

▪ Support the mission, vision & strategic plan of providing the Hartford community and beyond with the best, most
innovative, and technologically advanced cardiovascular and specifically, heart failure care.

Pre, intra & postoperative
Continued collection by
Analytics Administrator

Parameters of RV Dilation
CVP
CVP/PCWP
LV/RV end diastolic diameter

*Permission has been obtained from analytics
administrator for provision of deidentified data for
reorganization into a risk score by project owner

REFERENCES

Significance of The Project to Hartford Healthcare….

Data Collection

Background
Significance
Participation

PAS
PAD
SV

▪ Distribute the one-page fact sheet and pocket reference to
providers involved in the care of LVAD patients
▪ Post the one-page fact sheet and reference card in the

Education

Parameters of Pulmonary Hypertension

The Plan for Data Collection and Analysis

14

98
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Descriptive Analysis
Perioperative Trends
ANOVA: Predictors of
worsening right heart function
Incidence of RHF before and
during implementation
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Appendix K
RHF Risk Assessment Provider Information Sheet
Add 1 Point for Each Category if at Least One Parameter
Applies

Problem

Evidence

Plan

Right heart
failure is the
primary cause of
morbidity and
mortality
following LVAD
placement
Lack of a
comprehensive
tool for
assessing
impending right
heart failure

Combining right
heart failure risk
predictors is
more reliable
than using
individual
parameters
Risk is dynamic
throughout the
periopera ve
phases of care

Develop,
implement and
evaluate a
comprehensive
right heart
failure risk
assessment tool
for LVAD
recipients

Category 1: Pulmonary Resistance:
o
PAPI (PAS-PAD/CVP ) < 2.0
Category 2: Right Ventricular Dilation:
o
CVP >16
o
CVP/PCWP > 0.5
Category 3: Right Ventricular Function:
o
REF < 25
o
RVSWI >300
o
> Mild RV dysfunction on echo
o
TAPSE < 1.6
Category 4: Renal /Liver Function
o
Creatinine >2
o
New CVVH, HD
o
MELD Score >17
Category 5: Support
o
> 1 Inotropic or vasopressor medication
o
Mechanical ventilator dependence
o
IABP
o
RVAD
o
ECMO
Total Points
RHF Risk Score Interpretation: 4-5 Highest risk
2-3 Intermediate risk
0-1 Lowest risk

1.
What can you do?

✓
✓
✓

0-1 Point

2.
3.

Assure parameters needed to assess risk are documented
Calculate a risk score using the risk assessment tool
Include RHF risk assessment in patient presentation, hand-offs,
and care planning
Please contact Mary-Ann Cyr APRN

99

Instructions
Calculate: PAPI = PA systolic – PA diastolic pressure
Central venous pressure
Add 1 point for each category if at least one parameter applies
Total points and use RHF risk score interpretation key to assign
lowest,
The intermediate or highest risk
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Appendix L
Laminated Reference Card
FRONT

BACK
Right Heart Failure Risk Score Calculation Instructions
1. Calculate PAPI: PAPI = PA systolic pressure – PA diastolic pressure
Central venous pressure
2. Add 1 point for each category if at least one parameter applies
3. Total points and use RHF risk score interpretation key to assign lowest,
intermediate or highest risk
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Appendix M
Sample Hand-off Work Sheet with Addition of RHF Risk Score Entry

Patient
Name
Age
DOB
MRN
Unit/room
Code Status
LOS
Attending
Service

Summary

Procedures To
Notes
do/Pending

Neuro:
CV:
Resp:
GI:
GU:
Heme:
PMH/PSH/SH ID:
Endo:
Baseline Cr
Skin:
HGB A1C
Preop Wt.
RHF Risk
Score

Lines/Tubes

Date
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Appendix N
Provider Survey Information Sheet
Principal Investigator: Mary-Ann Cyr APRN Cardiothoracic Surgery
Co-Investigator:
Title of Project: Assessing Risk for Right Heart Failure After LVAD Implantation
You are invited to participate in this survey for providers feedback regarding the RHF risk
assessment instrument. I am an APRN in Bliss 9I at Hartford Hospital and a Doctor of Nursing Practice
candidate at Yale School of Nursing, and I am interested in finding out how to best assess risk for right
heart failure following implantation of a left ventricular assist device as this is the primary cause of
postoperative morbidity and mortality.
Your participation in this project will require completion of the linked questionnaire. This should
take approximately 10 minutes of your time. Your participation will be anonymous, and you will not be
contacted again in the future. Your participation is completely voluntary. You do not have to answer any
question that you do not want to answer for any reason. You will not be paid for being in this project. This
survey does not involve any risk to you. This project will provide no direct benefit to you today, but the
knowledge that we gain may benefit others in the future. Your doctor and other medical providers do not
have access to any information that you provide. Your access to and quality of healthcare will not be
affected in any way.
Please complete the linked survey. Once you do that, your participation will end.
Thank you.
Who you can call if you have questions about this study:

Questions about:

Contact

Phone #

the project, project-related treatments, or a
research related injury

Mary-Ann Cyr

(203) 232-0923

your rights as a project participant

An IRB Representative

(860) 972-2893

the research in general

Vice President, Research

(860) 972-2893

a confidential issue that you would like to
discuss with someone not associated with
project

Patient Advocates

(860) 972-1100
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Appendix O
Implementation Provider Survey
Please choose a rate the following with:
5 = Strongly agree
4 = Agree
3 = Neither agree nor disagree
2= Disagree
1 = Strongly disagree

The RHF risk assessment is useful.

1 2 3 4 5

The RHF risk assessment was simple to use.

1 2 3 4 5

The RHF risk assessment impacted clinical decision-making.

1 2 3 4 5

The RHF risk assessment was valuable in discussing LVAD patients’ clinical care.

1 2 3 4 5

The RHF risk assessment should be used routinely for all LVAD patients.

1 2 3 4 5

I will continue to use the RHF risk assessment in my evaluation of LVAD patients

1 2 3 4 5

Comments:
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________
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Appendix P
Case Reports
Patient A.
Patient A was diagnosed with NYHA class IV heart failure prior to admission. He was
admitted with an INTERMACS profile two, consistent with decompensation on inotropic
support and an admission diagnosis of cardiogenic shock. Incomplete prehospital data did not
allow calculation of a RHF risk score. However, available data revealed a minimal score of two
and a maximal possible score of three, indicating an intermediate risk for RHF failure. Fifteen
days after admission, the RHF risk score rose to four, indicative of the highest risk for
progression to right heart failure. An increased risk score was attributed to worsening pulmonary
hypertension and a declining right ventricular ejection fraction. Mechanical support had been
added however this did not contribute to the increased score as a point had already been awarded
for the continued inotropic medication requirement. On postoperative day six, the right heart
failure risk score remained a four. Worsening pulmonary hypertension, declining RV ejection
fraction, an elevated creatinine, an elevated MELD score, and continued inotropic support
contributed to a persistent score representing highest risk for progression to debilitating right
heart failure (see Table 3).
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Table 3
Patient A: Right Heart Reserve Parameters and Right Heart Risk Scores
Phase of Care

Prehospital

Preoperative

Intraoperative

Postoperative

Parameter
Admission to Insertion days)
Insertion to Postoperative (days)
Admission Diagnosis
NYHA Class
INTERMACS Profile
Pulmonary Hypertension
PAPi
RV Dilation
CVP
CVP:PCWP
RV Function
RVEF/REF
RVSWI
RV on Echo
TAPSE
Renal/liver Function
Creatinine
Dialysis
MELD
Support
Inotrope
Vasopressor
Ventilator
IABP
RVAD
ECMO
Additional
PAS
PAD
PCWP
Total Bilirubin
Sodium
INR
Risk Score
RHF Risk

15
6
CS
IV
2
2.0

2.0

1.2

10
0.48

5
0.23

9

20

18

Mild

Moderate

2.0
No
19.6
Milrinone
No
No
No
No
No

Milrinone
No
No
Yes
No
No

48
26
48

25
15
22
0.7
126
1.2
4
High

>2
Intermediate

2.2
No
19.6
Milrinone
No
Yes
Yes
No
No

Dobutamine
No
No
No
No
No
31
20

>3
>Intermediate

0.2
2.0
13 0
4
Highest

CS=Cardiogenic Shock, Highlighted Values Contributed to RHF Risk Score for Each Phase of care
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Patient B.
Patient B was diagnosed with NYHA class III heart failure prior to admission. The
patient was admitted with an INTERMACS profile three, consistent with stability on inotropic
support and elective LVAD implantation. Incomplete prehospital and preoperative data did not
allow calculation of a RHF risk score. However, available data revealed a low risk for RHF with
a maximal possible score of one. An intermediate intraoperative risk score was attributable to
mild RV dysfunction on echocardiogram and the addition of inotropic support. The patient’s
score of four on postoperative day three, represented highest risk for RHF and was attributable to
pulmonary hypertension, decreased right ventricular ejection fraction, elevated creatinine, and
continued inotropic support. Despite limited data, the patient was at lowest risk during the
prehospital phase of care. Prehospital data and clinical assessment upon admission may have
contributed to the foregoing of preoperative hemodynamic assessment. The RHF risk score did
increase at one or several points between the prehospital and postoperative phases of care. There
was no way to determine if the score increased, decreased, or persisted across the preoperative,
intraoperative, and postoperative phases of care (see Table 4).
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Table 4
Patient B: Right Heart Reserve Parameters and Right Heart Risk Scores
Phase of Care
Parameter
Admission to Insertion (days)
Insertion to Postoperative (days)
Admission Diagnosis
NYHA Class
INTERMACS Profile
Pulmonary Hypertension
PAPi
RV Dilation
CVP
CVP:PCWP
RV Function
RVEF/REF
RVSWI
RV on Echo
TAPSE
Renal/liver Function
Creatinine
Dialysis
MELD
Support
Inotrope
Vasopressor
Ventilator
IABP
RVAD
ECMO
Additional
PAS
PAD
PCWP
Total Bilirubin
Sodium
INR
Risk Score
RHF Risk

Prehospital

Preoperative

Intraoperative

Postoperative

2
3
PL
III
3
5.3

1.2

3
0.38

10

21
Normal

Mild

1.1
No
6.0
No
No
No
No
No
No

No
No
No
No
No
No

1.2
No
19.6
Milrinone
No
Yes
No
No
No

Milrinone
No
No
No
No
No

>2
>Intermediate

0.2
5.6
135
4
Highest

32
16
8

>0
Lowest

0.2
136
1.8
>0
>Lowest

PL = Planned LVAD, Highlighted Values Contributed to RHF Risk Score for Each Phase of Care
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Patient C.
Patient C was diagnosed with NYHA class III heart failure prior to admission. The
patient was admitted with an INTERMACS profile one, consistent with cardiogenic shock
despite escalating support. Incomplete prehospital data did not allow a right heart failure risk
score calculation. However, available data revealed lowest or possibly intermediate risk for right
heart failure with a minimum score of one and a maximal possible score of two. Eleven days
after admission, an intermediate risk was defined by a preoperative score of two, attributable to a
reduced right ventricular ejection fraction. A point for needed support had been earned for the
continuation of a prehospital inotropic medication. The risk score did not reflect the additional
support required to maintain intermediate risk during this phase of care. On postoperative day
two all support had been successfully discontinued reducing the risk score to one. Though
pulmonary hypertension worsened, all other parameters improved leading to a score representing
lowest risk for progression to RHF (see Table 5).
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Table 5
Patient C: Right Heart Reserve Parameters and Right Heart Risk Scores
Phase of Care
Parameter
Admission to Insertion (days)
Insertion to Postoperative (days)
Admission Diagnosis
NYHA Class
INTERMACS Profile
Pulmonary Hypertension
PAPi
RV Dilation
CVP
CVP: PCWP
RV Function
RVEF/REF
RVSWI
RV on Echo
TAPSE
Renal/liver Function
Creatinine
Dialysis
MELD
Support
Inotrope
Vasopressor
Ventilator
IABP
RVAD
ECMO
Additional
PAS
PAD
PCWP
Total Bilirubin
Sodium
INR
Risk Score
RHF Risk

Prehospital

Preoperative Intraoperative Postoperative

10
2
CS
III
1
5.5

1.8

1.5

2
0.26

9
0.64

10

12

28

Normal

Normal

1.5
No
6.0
Milrinone
No
No
No
No
No
19
8
7

>1
>Lowest

Milrinone
Dobutamine
No
Yes
Yes
No
No
47
24
14
0.4
136
1.0
3
Intermediate

0.8
No
6.0
Milrinone
Dobutamine
No
Yes
Yes/No
No
No

No
No
No
No
No
No
26
11

>1
>Lowest

0.3
2.0
136
1
Lowest

CS = Cardiogenic Shock, Highlighted Values Contributed to RHF Risk Score for Each Phase of Care
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Patient D.
Patient D was diagnosed with NYHA class IV heart failure prior to admission. The
patient was admitted with an INTERMACS profile two, consistent with decompensation on
inotropic support and an admission diagnosis of cardiogenic shock. Incomplete data did not
allow calculation of a prehospital risk score. However, available data revealed at least
intermediate risk with a minimum score of two and potentially highest risk with a maximal
possible score of four. The CVP did not contribute to the score yet was near high enough to
increase risk as well. Twenty-four days following admission, the patient’s risk score was three,
representing intermediate risk for RHF. Despite insufficient data, intraoperatively, the patient
continued to have at least intermediate and potentially highest risk for RHF with a minimal score
of three. Though two additional inotropic and vasopressor medications were required during this
phase of care, they did not contribute to an increased risk score as the patient had earned a point
for continuation of the prehospital inotropic infusion. On postoperative day five, the patient
remained on one inotropic infusion. Persistent intermediate to potentially highest risk for RHF
was represented by a minimum score of three and a maximal possible score of four. The risk
score was attributable to worsening pulmonary hypertension, declining RV ejection fraction, and
ongoing inotropic medication requirement, though the amount of required support decreased (see
Table 6).
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Table 6
Patient D: Right Heart Reserve Parameters and Right Heart Risk Scores
Phase of Care
Parameter
Admission to Insertion (days)
Insertion to Postoperative(days)
Admission Diagnosis
NYHA Class
INTERMACS Profile
Pulmonary Hypertension
PAPi
RV Dilation
CVP
CVP:PCWP
RV Function
RVEF/REF
RVSWI
RV on Echo
TAPSE
Renal/liver Function
Creatinine
Dialysis
MELD
Support
Inotrope
Vasopressor
Ventilator
IABP
RVAD
ECMO
Additional
PAS
PAD
PCWP
Total Bilirubin
Sodium
INR
Risk Score
RHF Risk

Prehospital

Preoperative Intraoperative Postoperative

24
5
CS
4
2

15

1.8

1.8

1

8

12

11

Moderate
1.4

Moderate

1.2
No
6.0
Milrinone

Milrinone

No
No
No
No
No

No
No
Yes/No
No
No

>2
>Intermediate

35
17
28
1.5
133
1.1
3
Intermediate

Severe

1.1
No
1.1
Milrinone
Dobutamine
Epinephrine
Yes
No
No
No

Milrinone
No
No
No
No
No

33
19
3.6
134
>2
>3
>Intermediate >Intermediate

CS=Cardiogenic Shock, Highlighted Values Contributed to RHF Risk Score for Each Phase of Care
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